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Abstract 
In advanced dementia, patients commonly experience burdensome medical 
interventions that may be of limited clinical benefit and do not promote a good quality of life 
and death. This thesis objective is to better understand and improve medical decision-making 
in advanced dementia among physicians, relatives of persons with dementia, and professional 
guardians, as well as to examine associations between decision-making supports and health 
outcomes in both decision-makers and patients. To this end, three studies were conducted. 
Findings revealed that having had a goals of care discussion with a physician helped proxies 
perceive that the resident may have a poor prognosis, which was in turn associated with the 
receipt of fewer burdensome interventions. Decision support tools reduced decisional 
conflict, increased knowledge, and shifted preferences in favor of foregoing antibiotics in 
advanced dementia among various decision-makers. Lastly, proxies were more likely to 
consider assisted dying in advanced dementia than physicians, and about half of the 
participants in both groups reported continuous deep sedation to be an appropriate option for 
this population. This thesis addresses many global public health priority topics such as 
dementia and palliative care, and has significant implications for the improvement of medical 
decision-making in advanced dementia.  
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Zusammenfassung 
Patienten mit fortgeschrittener Demenz werden häufig belastenden medizinischen 
Interventionen unterzogen, ohne dass dabei eine Verbesserung der Lebensqualität zu 
erwarten ist. Ziel dieser Dissertationsarbeit ist es, medizinische Entscheidungsfindungen von 
Ärzten, Angehörigen, und Berufsbeiständen im Kontext von fortgeschrittener Demenz zu 
verstehen und verbessern, sowie den Zusammenhang zwischen Entscheidungshilfen und 
gesundheitlichen Outcomes von Entscheidungsträgern und Patienten zu untersuchen. Zu 
diesem Zweck, wurden drei Studien durchgeführt. Die Ergebnisse zeigten, dass Angehörige, 
die die Behandlungsziele mit einem Arzt besprochen hatten, dazu neigten die Prognose des 
Bewohners als schlechter wahrzunehmen. Diese Wahrnehmung war mit einer geringeren 
Durchführung von belastenden Interventionen verbunden. Entscheidungshilfen in diversen 
Entscheidungsträgergruppen führten zu reduziertem Entscheidungskonflikt, erhöhtem 
Wissen, und gesteigerten Präferenzen für den Antibiotika-Verzicht bei fortgeschrittener 
Demenz. Stellvertreter im Vergleich zu Ärzten neigten dazu Sterbehilfe für Demenzpatienten 
zu befürworten, und etwa die Hälfte der Studienteilnehmer in beiden Gruppen hielt 
kontinuierliche tiefe Sedierung für eine geeignete Option für diese Population. Diese 
Dissertationsarbeit befasst sich mit globalen Gesundheitsthemen wie Demenz und Palliative 
Pflege und hat erhebliche Implikationen für die Verbesserung von medizinischer 
Entscheidungsfindung bei fortgeschrittener Demenz. 
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1. Introduction 
Dementia afflicts more than 50 million people worldwide and is one of the most 
common causes of death in Switzerland (Federal Statistical Office FSO, 2017; World Health 
Organization, 2015a). In advanced dementia, patients have profound deficits and experience 
repeated complications (Hendriks, Smalbrugge, Hertogh, & van der Steen, 2014; Mitchell et 
al., 2009). As a result, these patients commonly experience burdensome interventions that 
may be of limited benefit and do not promote a good quality of life (Gozalo et al., 2011; 
Meier, Ahronheim, Morris, Baskin-Lyons, & Morrison, 2001; Mitchell et al., 2009; Mitchell, 
Morris, Park, & Fries, 2004c; Mitchell et al., 2014; Mitchell, Teno, Roy, Kabumoto, & Mor, 
2003; Morrison & Siu, 2000b). 
Because of the impaired decisional capacity that accompanies advanced dementia, 
legally authorized decision-makers, mostly relatives but also professional guardians, along 
with physicians are responsible for medical decision-making (A. B. Cohen, Wright, Cooney, 
& Fried, 2015; Givens, Kiely, Carey, & Mitchell, 2009). However, these decision-makers 
report inadequate decisional support and burdensome decision-making (Engel, Kiely, & 
Mitchell, 2006; Givens et al., 2009; Pautex et al., 2013; You et al., 2015). Consequently, they 
frequently make treatment decisions on behalf of the patient that do not align with the 
patient’s goals of care (D'Agata & Mitchell, 2008; Mitchell et al., 2009; 2014; 2017). Despite 
substantial progress in advanced dementia research, our understanding of medical decision-
making and its impact on outcomes that enable healthy ageing of both decision-makers and 
patients is limited (Mitchell et al., 2012; van der Steen, Sternberg, & Volicer, 2017b; World 
Health Organization, 2017). 
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The purpose of this thesis is to better understand and promote medical decision-
making in advanced dementia among physicians, relatives of persons with dementia, and 
professional guardians, and to examine associations between decision-making supports and 
health outcomes in both decision-makers and patients. To this end, the first chapter will apply 
the concept of Healthy Ageing to terminal diseases such as dementia and motivate hypotheses 
in the more specific context of advanced dementia. Next, I will present treatment decisions 
for common complications in advanced dementia, discuss the use of controversial practices 
(e.g., assisted dying), and highlight challenges that may arise when making decisions on 
behalf of these patients. After reviewing the existing research on the promotion of high-
quality decision-making and care, I will present three studies that were conducted for this 
thesis and contribute to that literature. While studies 1 and 2 provide novel insights about the 
role of different forms of support in improving decision-making and care, study 3 explores 
perceptions about controversial practices in advanced dementia. In the third and last chapter, 
I will summarize these three studies, discuss their findings, and present their strengths and 
limitations. Lastly, I will conclude by illustrating the implications of this work for future 
research and for the management of advanced dementia. 
1.1. Healthy Ageing 
Healthy Ageing is an intergenerational and intercultural common life-goal. Every 
human being wishes to age as healthy as possible. But what does healthy ageing mean in the 
context of chronic and terminal illnesses such as Alzheimer’s disease and other dementias? 
The concept of Healthy Ageing refers to the maintenance of functional quality of life 
even in the face of disease (Martin, Jäncke, & Röcke, 2012a; Martin, Schneider, Eicher, & 
Moor, 2012b; Scholz, König, Eicher, & Martin, 2015; World Health Organization, 2015b). 
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Individuals are no longer categorized into healthy versus unhealthy, but are instead thought to 
be situated on a continuum of functionality going from less functional to fully functional. 
Individuals are thus functional when their health is maintained or stabilized as suggested by 
the the functional Quality of Life model (fQoL) (Martin, Schneider, Eicher, & Moor, 2012b). 
Further research has examined the stabilization of health as an indicator of well-being 
(Martin, Jäncke, & Röcke, 2012a; 2016; Scholz et al., 2015). In this context, the homeostasis 
of health is a focal goal throughout every individual’s lifespan (Martin, Jäncke, & Röcke, 
2012a; Scholz et al., 2015; Wilkening & Martin, 2003). 
In line with this research, the World Health Organization (WHO) has defined Healthy 
Ageing as the process of developing and maintaining the functional ability that enables well-
being in older age (page 28; World Health Organization, 2015b). This concept has been more 
specifically defined in a framework that suggests three domains influencing an individual’s 
ability to be functional: 1. intrinsic capacities (physical and mental abilities or impairments); 
2. functional ability (health attributes enabling an individual to act as desired); and 3. 
environment (micro- and macro-level). An individual’s ability to function depends on the 
interaction between their intrinsic capacities (e.g., personal and health characteristics) and 
their environment. Resources from the environment may include people and their 
relationships (e.g., caring family members or open health care provider staff), but also health 
policies (e.g., guidelines on palliative care in dementia), and supporting systems or services 
(e.g., specialized dementia care unit). Successful activation of adequate resources from these 
domains can enable healthy ageing despite a chronic and terminal illness. 
Most individuals successfully manage to maintain high levels of functioning in older 
age,(Martin, Jäncke, & Röcke, 2012a) but maintain functioning is more challenging for those 
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affected by chronic and terminal illnesses such as dementia (Scholz et al., 2015). In advanced 
dementia, the intrinsic capacities of the patient are severely impaired,(Mitchell et al., 2009) 
and there is currently no therapy to cure dementia and thus stabilize functions. However, 
stabilization may be achieved using palliative medicine to control symptoms and increase 
comfort (van der Steen et al., 2014). Patients with advanced dementia are unable to 
communicate needs or ask for support because of the cognitive impairments that accompany 
the condition. Consequently, the patient’s environment (e.g., health care system, clinical 
guidance, dementia policies, or legal authorized decision-makers) is responsible for 
anticipating, recognizing, and fulfilling the patient’s needs to enable well-being with 
dementia and to do so until death.  
It is challenging to determine the specific elements that need to be adjusted in order to 
maintain functioning in old age for a given individual (Martin, Jäncke, & Röcke, 2012a). In 
advanced dementia, despite increasingly dementia-friendly societies, progress in palliative 
medicine, and caring families, most patients still experience a poor quality of life and death.  
1.2. Advanced Dementia 
Dementia is a terminal disease defined by neuropathologic changes or biomarkers, 
which cause memory and other cognitive abilities to gradually worsen, leading to confused 
behavior (Jack et al., 2018; World Health Organization, 2017). As a result, the person’s 
ability to carry out complex but essential tasks in daily life is compromised. Dementia is an 
umbrella term that covers a wide range of diseases, the most common forms are Alzheimer 
disease, which contributes to 60-70% of cases, vascular dementia, dementia with Lewy 
bodies, and others defined as frontotemporal dementia (World Health Organization, 2015a).  
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1.2.1. Epidemiology 
More than 50 million people worldwide are affected by dementia, a number that 
roughly corresponds to the population of Spain (Alzheimer's Disease International, 2013). 
With an ageing global demographic, this number is expected to increase by 50% by 2030, 
and even reach 136 million by 2050 (World Health Organization, 2015a). In Switzerland, 
dementia afflicts about 133 thousands people and is one of the most common causes of death 
(Alzheimer Europe, 2014). Every three seconds someone in the world begin to develop 
dementia (Alzheimer's Disease International, 2015). The average life expectancy from the 
onset of dementia until death is approximately five years (Xie, Brayne, Matthews, Medical 
Research Council, 2008). One in three people over the age of 65 die with dementia (Brayne, 
Gao, Dewey, Matthews, Medical Research Council, 2006). Most people with dementia die in 
nursing homes (in the United Sates, 67%; the Netherlands, 92%; Belgium, 66%; and 
England, 60%), making those facilities key settings for end-of-life care (Houttekier et al., 
2010; Mitchell, Teno, Miller, & Mor, 2005). 
Given the increasing prevalence of dementia, the burden places on current and future 
global public health is enormous and growing. In 2015 associated global costs were estimated 
to be as high as USD 818 billion annually (or CHF 767 billion) and included direct medical, 
social care, and informal care costs (World Health Organization, 2017). The World Health 
Organization (WHO) anticipates this cost to more than double by 2030, which could have 
dramatic consequences on a variety of social and health services including long-term care 
systems such as nursing homes. Costs vary according to dementia severity; the costs 
associated with advanced dementia are more than twice as high as those associated with mild 
dementia (Quentin, Riedel-Heller, Luppa, Rudolph, & König, 2010). 
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In light of the severity of the situation and its dramatic forecasts, the WHO has 
published a global action plan on the public health response to dementia for the time period 
of 2017 through 2025 and simultaneously established a global dementia observatory (World 
Health Organization, 2016; 2017). The action plan lists several action areas of high priority, 
and this thesis addresses action areas on treatments, medical decision-making, and support 
(see action areas 4, 5, and 7; World Health Organization, 2017). The Global Dementia 
Observatory is a web-based platform that aims to track global progress related to dementia in 
approximately 50 countries (World Health Organization, 2016). The platform will enable 
authorities including health care providers and researchers to easily access and share 
documents such as global reports, policies, and guidelines on dementia care. While the 
observatory is positioned to be an important tool in coordinating and ensuring dementia-
friendly care at a global scale, it also implies a need for evidence-based, standardized 
guidelines that form the basis of such coordination. 
Dementia is a terminal condition and, in the face of an ageing population, more and 
more people are expected to live and die with dementia. The societal burden of advanced 
dementia is substantial and growing. In response to this alarming situation, the WHO has 
recently published an action plan on dementia and developed the global dementia 
observatory. 
1.2.2. Clinical Course 
Advanced dementia is characterized by a prolonged trajectory of severe disability, 
associated with major impairments in the last year of life (Hendriks et al., 2014; Mitchell et 
al., 2009). Reisberg and colleagues have developed the Global Deterioration Scale for the 
assessment of primary degenerative dementia (Reisberg, Ferris, de Leon, & Crook, 1982). 
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The scale states advanced dementia to be defined by an inability to recognize family 
members, an inability to speak more than five words, by being bedbound, incontinent of urine 
and stool, and totally dependent in activities of daily living. Although this definition has been 
put forward in 1982, it has not been until a quarter-century later that the clinical course of 
patients with advanced dementia has been well described. 
The Choices, Attitudes, and Strategies for Care of Advanced Dementia at the End-of-
Life (CASCADE) study constitutes the first description of the clinical course of advanced 
dementia (Mitchell et al., 2009). This study followed 323 nursing home residents with 
advanced dementia over a period of 18 months and was conducted in 22 nursing home 
facilities of the greater Boston area. Over the 18-month study period, 55% of residents died, 
86% developed a feeding problem, 41% had pneumonia, and 53% had a febrile episode. 
These findings revealed that advanced dementia is characterized by a high mortality rate, and 
that complications such as infections, feeding problems, fever, dehydration, or other illnesses 
should be expected. Not only is it common for complications to occur at all but they are also 
expected to re-occur. Repeated pneumonia episodes are typical of the end-stage of the 
disease.  
As a consequence of the trajectory of severe disability, patients commonly experience 
significant distress symptoms (Hendriks et al., 2014; Mitchell et al., 2009; van der Maaden, 
van der Steen, de Vet, Hertogh, & Koopmans, 2016; van der Steen, Pasman, Ribbe, van der 
Wal, & Onwuteaka-Philipsen, 2009b). In CASCADE, distress symptoms observed among the 
323 residents during the 18-month study period included agitation (54%), dyspnea (46%), 
aspiration (41%), pressure ulcers (39%) and pain (39%) (Mitchell et al., 2009). These 
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symptoms frequently increase in the last days of life (Hendriks et al., 2014; van der Maaden 
et al., 2016). 
This description of the clinical course of advanced dementia has been cross-validated 
in many other countries, revealing similar trajectories of disability and high mortality rate in 
advanced dementia (Hendriks et al., 2016; Mitchell et al., 2009; van der Steen, Pasman, 
Ribbe, van der Wal, & Onwuteaka-Philipsen, 2009b; Vandervoort et al., 2013). However, 
evidence about the clinical course of Swiss patients is lacking. The Zurich Life and Death 
with Advanced Dementia (ZULIDAD) study will be the first to describe the clinical course 
and quality of life and dying of residents with advanced dementia in Switzerland (Eicher et 
al., 2016). ZULIDAD is a prospective cohort study conducted in 11 nursing homes in the 
greater Zurich area that followed triads of residents with advanced dementia, their relatives, 
and primary nurses. The data collection was recently completed. Forthcoming findings from 
this study may provide novel insights about the nursing situation and needs of those affected 
by advanced dementia in Switzerland.  
1.2.3. Treatments for Common Complications 
Clinical complications experienced by patients with advanced dementia are 
commonly accompanied by distress symptoms at the end of life (Hendriks et al., 2014; 
Mitchell et al., 2009; van der Maaden et al., 2016; van der Steen, Pasman, Ribbe, van der 
Wal, & Onwuteaka-Philipsen, 2009b). Treatment decisions thus have to be made on behalf of 
the patient to potentially cure the underlying complication, reduce distress symptoms and 
promote comfort.  
About two-thirds of people with advanced dementia die from pneumonia (Osler, 
1898; Thomas, Starr, & Whalley, 1997; van der Steen et al., 2006; van der Steen, Ooms, van 
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der Wal, & Ribbe, 2002). Decisions related to the use antibiotics are the most common end-
of-life decisions in this population followed by decisions such as those relating to the use of 
parenteral therapy, tube feeding, or hospitalization (Di Giulio et al., 2008; Hendriks et al., 
2016; Mitchell et al., 2009). Of the 323 residents with advanced dementia in the CASCADE 
study, 34% received parenteral therapy, 17% were hospitalized, 10% were taken to the 
emergency room, and 8% were tube fed. Of these 32, 41% underwent burdensome 
interventions in their last three months of life (Mitchell et al., 2009). Research has shown that 
these interventions may be of limited clinical benefit and may not promote comfort-focused 
care (Gozalo et al., 2011; Meier et al., 2001; Mitchell et al., 2003; 2009; 2014; Mitchell, 
Morris, Park, & Fries, 2004c; Morrison & Siu, 2000b; van der Steen et al., 2014). 
The use of antibiotics in patients with advanced dementia illustrates well the 
uncertainty about the benefit-to-harm ratio of most curative treatments in this frail and dying 
population. The Study of Pathogen Resistance and Exposure to Antimicrobials in Dementia 
(SPREAD) investigated antimicrobial exposure in 363 residents with advanced dementia in 
35 nursing home facilities of the greater Boston area over 12 months (Mitchell et al., 2014; 
Mitchell, Shaffer, Kiely, Givens, & D'Agata, 2013). Among 496 suspected infections in these 
residents, 72% were treated with antimicrobials. Of these, 56% were treated inappropriately 
as there was inadequate clinical evidence of a bacterial infection. Over the course of the 
study, 67% of the residents became colonized at some point with antibiotic resistant bacteria, 
and exposure to an antibiotic was the strongest risk factor for bacterial colonization. Patients 
commonly receive antibiotics during their last days of life and often in addition to invasive 
rehydration therapy (D'Agata & Mitchell, 2008; Hendriks et al., 2014; van der Steen et al., 
2017a). 
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Antimicrobials may effectively treat infections, but they are frequently inappropriate 
in advanced dementia (Mitchell et al., 2014). First, the diagnosis of a suspected infection 
requires burdensome procedures. For example, to diagnose a respiratory tract infection the 
already frail resident is transferred to the hospital to undergo a chest X-ray test. 
Hospitalization can be traumatic for both patients and family members, and is associated with 
poor outcomes in these frail patients (Dewing & Dijk, 2016; Epstein-Lubow et al., 2012). 
Second, antimicrobials may be used in the absence of infection because antibiotics are 
frequently administered without meeting minimal criteria for administration (D'Agata, Loeb, 
& Mitchell, 2013). Third, the administration of the treatment itself often requires an intensive 
procedure that can cause discomfort for the frail patient. Because of swallowing difficulties 
that accompany advanced dementia, antibiotics are commonly given via infusion, which 
require the placement of a needle in the vein (D'Agata & Mitchell, 2008). Fourth, significant 
side effects of antibiotics add to the aforementioned aspects, further suggesting that potential 
clinical benefit may be outweighed by adverse consequences. Antimicrobials can provoke 
diarrhea, allergic reactions (e.g., skin rashes), nausea, or vomiting. The benefit-to-harm ratio 
of antimicrobial use on survival and comfort in advanced dementia remains unclear (Givens, 
Jones, Shaffer, Kiely, & Mitchell, 2010; van der Steen, Lane, Kowall, Knol, & Volicer, 
2012). Lastly, most treatments are prescribed without taking into account the high likelihood 
of the complication re-occuring and in unawareness of the terminal condition of these dying 
patients (Mitchell et al., 2009; 2014; Mitchell, Kiely, & Hamel, 2004a; van der Steen, 
Onwuteaka-Philipsen, Knol, Ribbe, & Deliens, 2013). 
Another major issue of the extensive misuse of antibiotics is the spread of Multi-
Drug-Resistant-Organisms (MDROs). Antimicrobial overuse may result in the development 
of MDROs, which are bacteria that have become ‘resistant’ to many commonly used 
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antibiotics. In SPREAD, most treatment decisions were inappropriate and antibiotic resistant 
bacteria were present in most residents with advanced dementia (Mitchell et al., 2014). These 
bacteria may cause antibiotics to not work when really needed and provoke other infections 
which may cause death or prolonged illnesses, leading to long hospital stays, isolation 
measures, and increased costs (Kronenberg, Zanetti, Piffaretti, & Mühlemann, 2008; World 
Health Organization, 2014a). Bacteria can be transmitted from individual to individual. 
MDROs thus affect not only human health, but they also result in negative public health 
outcomes and tremendous, preventable costs for the health-care sector (World Health 
Organization, 2014a). Therefore, the reduction of antibiotic resistant infections is a priority of 
the World Health Organization and a worldwide concern (Ho, Tambyah, & Paterson, 2010; 
World Health Organization, 2014b). 
In this context, to control distressing symptoms and promote comfort in frail patients 
with advanced dementia other treatments than antibiotics may be considered. Palliative Care 
focuses on relieving symptoms, pain, and mental distress and recent guidelines suggest 
prioritizing this approach among patients with advanced dementia (Swiss Academy of 
Medical Sciences, 2017; van der Steen et al., 2014). Pain, agitation, and shortness of breath 
are symptoms that may be effectively treated with standard palliative medications (Hendriks 
et al., 2014; Mitchell et al., 2009). A study in the Netherlands investigated symptoms and 
treatments and their associations with quality of life in the last 7 days of life among 330 
nursing home residents with advanced dementia (Hendriks et al., 2014). Their data showed 
that residents received opiods (77%), anxiolytic or hypnotic medication (57%) and palliative 
sedation (21%) when death was imminent. Not receiving these palliative treatments was 
associated with a lower quality of life in these patients.  
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Taken together, residents with advanced dementia commonly receive potentially 
aggressive interventions that may be of little clinical benefit and may not promote comfort at 
the end-of-life. In the specific case of antibiotic treatments, there is a clear need to reduce the 
amount of antibiotics prescribed to residents with advanced dementia, which would improve 
comfort in these residents and contribute to mitigating the public health threat of MDROs. 
Palliative care should be prioritized to relieve symptoms and improve the quality of life of 
these frail patients.  
1.2.4. Controversial End-of-Life Practices 
Advances in medicine and palliative medicine, in particular, have enabled 
considerable improvement of the health and life of patients with advanced dementia 
(Kavalieratos et al., 2016; van der Steen et al., 2014). However, certain contexts and 
situations may require considering the use of assisted dying and continuous deep sedation 
until death, which are controversial end-of-life practices. 
In the fear of an impoverished existence with advanced dementia, patients with early 
onset dementia and remaining decisional capacity may wish to request physician-assisted 
suicide (Diehl-Schmid et al., 2017). Physician-assisted suicide refers to self-administration of 
lethal drugs that are provided by a physician (Radbruch et al., 2016). This procedure thus 
requires that the recipient is capable of maintaining and acting on that decision. This practice 
is legal in only a few states in the United States and a limited number of countries, including 
Switzerland (E. J. Emanuel, Onwuteaka-Philipsen, Urwin, & Cohen, 2016; Li et al., 2017). In 
2014, 742 cases of physician-assisted suicide were registered in Switzerland and, of these 6 
(0.8%) concerned persons with early-onset dementia capable of decision-making (Federal 
Statistical Office FSO, 2016). Patients with advanced dementia, however, cannot make such a 
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request because they are no longer capable of decision-making. In this case euthanasia may 
be performed, meaning that the physician administers the drugs that cause the person to die 
(Radbruch et al., 2016). The Netherlands, Belgium, and Luxembourg allow euthanasia for 
patients with advanced dementia under certain conditions and it must be explicitly requested 
in an advanced euthanasia directive (Neil, 2016). Following legalization, the proportion of 
Belgian individuals with a psychiatric disorder or dementia requesting euthanasia has 
increased from 0.5%, in 2002, to 3.0%, in 2013 (Dierickx, Deliens, Cohen, & Chambaere, 
2017). In line with this increase, the views toward assisted dying in dementia seem more 
accepting over time, although physicians seem more opposed than proxies (Bolt, Snijdewind, 
Willems, van der Heide, & Onwuteaka-Philipsen, 2015; Kouwenhoven et al., 2015; Rurup, 
Onwuteaka-Philipsen, Pasman, Ribbe, & van der Wal, 2006; Tomlinson & Stott, 2014; 
Tomlinson, Spector, Nurock, & Stott, 2015). 
Another controversial practice in advanced dementia is continuous deep sedation until 
death, which is an intensive palliative therapy used as a last resort when all alternative 
options have failed to alleviate the patient’s suffering (Miccinesi et al., 2006; Ziegler, 
Schmid, Bopp, Bosshard, & Puhan, 2018). Continuous deep sedation uses medications, 
administered until death with the aim of lowering the level of consciousness and relieving 
refractory symptoms of patients with a life expectancy of less than two weeks (Cherny, 
Radbruch, The Board of the European Association for Palliative Care, 2009). This practice 
has been commonly used in advanced cancer patients who experience extreme physical 
suffering in their last weeks (McCarthy, Phillips, Zhong, Drews, & Lynn, 2000; Miccinesi et 
al., 2006; Teunissen et al., 2007). Two studies suggest that this practice may also be used 
among advanced dementia patients, but there is no direct evidence on its appropriateness for 
this population (Anquinet et al., 2013; Hendriks et al., 2014). 
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Assisted dying and continuous deep sedation are controversial end-of-life practices in 
advanced dementia. Gaining deeper insights on the use of and perceptions about these 
practices would inform whether they should be seen as valid options in advanced dementia.  
1.3. Implications for Medical Decision-Making 
Advanced dementia is a terminal condition characterized by a prolonged trajectory of 
severe disability (Hendriks et al., 2014; Mitchell et al., 2009). Consequently, decisions about 
the use of treatments are frequent and, in a minority of cases, decisions may also concern 
controversial end-of-life practices such as assisted dying or continuous deep sedation. 
1.3.1. Decision-Makers 
Because of the impaired judgment that accompanies advanced dementia, and in the 
absence of a patient decree, medical decision-making is delegated to legally authorized 
representatives. Representatives are most often relatives of the person with advanced 
dementia (Givens et al., 2009). In the absence of relatives, however, professional guardians 
are appointed by a court and serve as designated, legally authorized representatives (A. B. 
Cohen et al., 2015). These representatives, along with health care providers, physicians but 
also nurses, are responsible for medical decision-making on behalf of the patient. Treatment 
decisions are guided by the patients’ care preferences as specified in advanced directives or 
as perceived by their proxies. Health care providers give their medical expertise based on the 
patients’ best interest. However, research has shown that most decisions made by these 
decision-makers do not align with the patient’s goals of care (D'Agata & Mitchell, 2008; 
Mitchell et al., 2009; 2014; 2017). 
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1.3.2. Burdensome Decision-Making 
It can be challenging to make medical decisions on behalf of a patient who is 
incapable of making decisions. While data on the experience of professional guardians 
making choices about end-of-life care is lacking, most relatives and physicians report 
burdensome decision-making due to uncertainty about patient’s preferences, lacking medical 
information, and challenging communication about end-of-life care (Engel et al., 2006; 
Givens et al., 2009; Pautex et al., 2013; You et al., 2015). 
Advance directives can provide information about the patient’s preferences, but prior 
research has shown that they are rarely being used in this population (Mitchell et al., 2012; 
Mitchell, Teno, Intrator, Feng, & Mor, 2007; Tjia, Dharmawardene, & Givens, 2018). A large 
study conducted in five states of the United States found that 61% of all 44,433 residents with 
advanced dementia had an advanced directive, and only 5% had specific directives regarding 
medication restrictions (Tjia et al., 2018). These findings suggest that four in ten residents 
with dementia lack any advanced directive and when it comes to decisions about medication 
almost none possessed any written recommendations. In the absence of an advance directive, 
treatment decisions are guided by the proxy’s perceptions of the patient’s care preferences. 
However, their perceptions may be inaccurate and even if there is a written request, the 
patient’s preferences might have changed over time (E. J. Emanuel, Fairclough, & Emanuel, 
2000; Harrison Dening, King, Jones, Vickestaff, & Sampson, 2016). 
As will be further discussed in the last chapter of this thesis, there are key aspects of 
dementia and treatment options that decision-makers need to be made aware of in order to 
ensure informed treatment decisions. The following fundamental medical information should 
be discussed and understood: 1. terminal condition of dementia; 2. expected re-occurence of 
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complications (e.g., repeated pneumonia episodes); 3. benefit-to-harm ratio related to 
treatment administration; 4. benefit-to-harm ratio related to treatment effects; and 5. 
alternatives to treatments. However, most family proxies are unaware of the terminal nature 
of advanced dementia and the poor prognosis (Mitchell, Kiely, & Hamel, 2004a). Most 
decisions about the use of antibiotics are made without taking into account the probability of 
the pneumonia episodes reoccurring (Mitchell et al., 2014). The benefit-to-harm ratio of 
treatments may not always be discussed, as it was the case in one-third of decisions about the 
use of feeding tubes in advanced dementia patients (Teno et al., 2011). Without clear 
information on benefits and harms of treatments, proxies may perceive decisions not to treat 
more difficult than decisions to treat and therefore prefer more aggressive treatments (Rabins, 
Hicks, & Black, 2011). 
Communication about end-of-life decisions is difficult for all decision-makers 
involved. Despite their primary role in decision-making, relatives recall involvement in only 
about 39% of treatment choices (Givens et al., 2009; 2015). When involved, relatives report 
high dissatisfaction with decision-making due to lack of counseling and support by health 
care providers; about half spent less than 15 minutes discussing goals of care (Engel et al., 
2006; Givens et al., 2009; Givens, Lopez, Mazor, & Mitchell, 2012). Relatives may have 
difficulties coping with the situation, discordant opinions with other family members about 
the ‘right’ decision, and may be overwhelmed by the turnover of different physicians (Vig, 
Starks, Taylor, Hopley, & Fryer-Edwards, 2007). Physicians, on the other hand, report 
challenging end-of-life communication with families due to difficulty accepting a poor 
prognosis, understanding benefit and harms of treatments, and due to disagreement about 
goals of care (You et al., 2015). The poor quality of communication may also be reflected in 
frequent disagreements on the content of these conversations (D. B. White et al., 2016a). 
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Decision-makers are influenced by their background and personal characteristics, such as 
coping strategies (Hinkka et al., 2002; Vig et al., 2007). 
Consequently, family proxies and physicians of advanced dementia patients 
experience high dissatisfaction with end-of-life decisions (Givens et al., 2012; Pautex et al., 
2013). Uninformed treatment decisions are frequent and may result in poor outcomes for the 
decision-maker, but also in subsequent over- or undertreatment of the patient (Mitchell et al., 
2009; 2014; 2017). Attention to and support for decision-making is needed to ensure that the 
decisions made on behalf of the patient with advanced dementia are in line with the patient’s 
goals of care are. 
1.4. Promoting High-Quality Medical Decision-Making 
High-quality decision-making is essential to high-quality care. Measuring the quality 
of medical decision-making is complex given the patients’ inability to take part in decision-
making or communicate whether a decision was appropriate.  
Delivering goal-directed care (i.e., making appropriate treatment decisions) requires 
an understanding of the patient’s preferences and the set of available treatment options 
(Mitchell et al., 2017; Rangel, Camerer, & Montague, 2008; van der Steen et al., 2014). A 
well-established, neuroeconomic framework to formalize decision-making suggests that any 
appropriate decision is the result of having sufficient knowledge of the range of feasible 
actions that are subsequently weighted according to their expected values allowing the most 
desirable option to be selected (Rangel et al., 2008). Outcomes associated with the selection 
are evaluated ex post to update the weights assigned to the corresponding options. Given the 
lack of counseling and unawareness about treatment options, proxies have insufficient 
knowledge and are frequently led to choose more aggressive treatments per default (Rabins et 
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al., 2011). As a result, they may not be satisfied with their decision and the subsequently 
observed negative outcomes. Applying the aforementioned decision-making model to 
decisions that are made on behalf of others, decisional support may promote high-quality 
decision-making by providing additional choice options. Moreover, it might do so by 
enabling those preferences (or decision weights) to be incorporated that would otherwise only 
be part of the patient’s value function and thus remain external to the actual decision-maker 
(Rangel et al., 2008). 
Palliative care has the potential to improve outcomes for all of those who are affected 
by dementia. This approach has been shown to increase decision-makers’ satisfaction with 
decision-making and improve quality of life by stabilizing functions and maximizing comfort 
of patients with advanced dementia (Kavalieratos et al., 2016; van der Steen et al., 2014). 
Palliative care defines treatment options for advanced dementia patients based on three goals, 
more than one of which may apply at the same time: 1. prolongation of life (e.g., curative 
treatments such as antibiotics); 2. maintenance of function (e.g., watchful waiting or 
treatment trial); and 3. maximization of comfort (e.g., medication to control pain and distress 
only) (Mitchell et al., 2017; van der Steen et al., 2014). While the maintenance of function 
and maximization of comfort should be prioritized in advanced dementia, it is also 
appropriate to prolong life if preferred (Swiss Academy of Medical Sciences, 2017; van der 
Steen et al., 2014). Although palliative care is a promising avenue for high-quality decisions, 
its implementation is still at its infancy and decision-makers may not be aware of the set of 
available treatment options offered by this approach. 
Proxy counseling by health care providers offers an opportunity to define the goals of 
care of the patient, go through the process of decision-making as described above, and 
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promote palliative care. Proxies who have had a goals of care discussion with health care 
providers are more likely to prefer comfort care (Mitchell et al., 2017). This suggests that 
proxy counseling can help promote decisions toward more comfort-focused care. Proxy 
counseling may also be key in promoting awareness of the limited remaining lifetime of 
advanced dementia patients. In CASCADE, residents of family members who had a better 
understanding of what to expect in advanced dementia underwent less burdensome 
interventions, such as hospitalizations, intravenous therapy, and tube-feeding in the last 
months of life (Mitchell et al., 2009). However, this association has only been shown in a 
small cohort of residents who had passed away. Given the communication challenges 
discussed in the preceding chapter, it seems crucial to advance our understanding of factors 
associated with optimal counseling and decision-making.  
Decision-support tools can improve decision-making by fostering communication and 
by informing and framing treatment choices (Stacey et al., 2014). In advanced dementia, the 
few decision-support tools that have been shown to improve knowledge and reduce 
decisional conflict of family decision-makers, and promote preferences for more comfort-
focused care (Einterz, Gilliam, Lin, McBride, & Hanson, 2014; Hanson et al., 2011; 2017; 
Mitchell, Tetroe, & O'Connor, 2001; Snyder, Caprio, Wessell, Lin, & Hanson, 2013; 
Volandes, Barry, Chang, & Paasche-Orlow, 2009a; Volandes, Paasche-Orlow, Barry, Gillick, 
Minaker, et al., 2009b). While these tools have been found to be effective, they are tailored to 
families only. Moreover, most of them are video-based, expensive and difficult to implement 
in health care settings. 
High-quality decision-making is critical in order to reflect the patient’s goals of care 
and can be promoted via proxy counseling and decision support tools. Decision-makers can 
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make appropriate treatment decisions if they understand the set of available care options and 
their consequences. While comfort-focused care may be the preferred palliative care 
approach in frail patients, palliative medicine can also provide curative treatment with the 
goal of prolonging life, if preferred. 
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2. Research Plan 
Advanced dementia is characterized by profound deficits and clinical complications 
that may result in a poor existence in the last years of life of patients (Hendriks et al., 2014; 
Mitchell et al., 2009). Medical decision-making by proxy surrogates and physicians is a 
means by which the patient can stabilize or maintain functional ability and thus obtain a 
better quality of life (World Health Organization, 2015b). However, processes of medical 
decision-making are frequently suboptimal, thereby limiting well-being and healthy ageing 
for both the decision-maker and the patient.  
2.1. Research Questions and Empirical Studies 
The research questions and empirical studies of this thesis are illustrated in Figure 1 
using an extension of the Quality of Care Donabedian model (Donabedian, 1988; Teno, 
Landrum, & Lynn, 1997).  
 
Figure 1. Illustration of research questions in studies 1-3 using the Quality of Care Model 
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According to this conceptual model, improved quality arises from on-going 
interactions between the following domains: Contexts, Processes, Systems of care, and 
Outcomes. The capacity of stakeholders to adapt and communicate in this environment is key 
to improve quality of decision-making. 
In advanced dementia, the contexts of decision-making are broadly divided into 
patients and decision-makers. Advanced dementia patients have a high mortality risk, poor 
health and quality of life (Hendriks et al., 2014; Mitchell et al., 2009). Decision-makers 
report a lack of information, challenging communication, high decisional conflict, and thus 
burdensome decision-making in general (Engel et al., 2006; Givens et al., 2009; Pautex et al., 
2013; You et al., 2015). Decision-making can be improved by proceses, which can be any 
kind of (im-)material support, such as proxy counseling or decision-support tools. The 
systems of care include the hospital, nursing home, or any special dementia care unit. 
Outcomes of decision-making on behalf of someone else are twofold (see Rangel et al., 2008 
internal and external states): the decision-makers’ outcomes and the observed patient’s 
outcomes. Given the complex nature of the contexts of decision-making and the systems of 
care, this thesis sought to address the following question:  
How can we better understand and promote medical decision-making in advanced 
dementia among various decision-makers? In particular, what is the relationship between 
decision-making supports (i.e., processes) and health outcomes of both decision-makers and 
patients?  
To address the main question of this thesis, we have explored medical decision-
making in three different, but complementary studies. All studies (1, 2, and 3) investigate 
contexts of decision-making. Studies 1 and 2 examine processes of decision-making such as 
RESEARCH PLAN 
 
23 
proxy counseling and decision-support interventions and their effects on outcomes in both 
decision-makers (studies 1 and 2) and patients (study 1 only). While study 2 is based on 
hypothetical situations, study 1 is conducted in nursing home settings and thus also addresses 
systems of care. Unlike studies 1 and 2, study 3 solely explores perceptions of decision-
makers about controversial end-of-life practices. The main research question of this thesis is 
thus split into two experimental questions and one exploratory question:  
How does proxy perception of prognosis relate to high-quality decision-making and 
care? (study 1) How do brief decision-support tools tailored to various decision-makers 
relate to high-quality decision-making? (study 2) When reducing burden may mean choosing 
death: what are the perceptions of various decision-makers about controversial end-of-life 
practices? (study 3, explorative) 
2.1.1. Study 1: How does proxy perception of prognosis relate to high-quality 
decision-making and care? 
Prognosis in advanced dementia is challenging and may influence care. Prior research 
has shown that rigorously derived mortality risk scores for advanced dementia are only 
moderately accurate in predicting 6-month survival (Mitchell, Kiely, Hamel, Park, Morris, et 
al., 2004b; Mitchell, Miller, Teno, Davis, & Shaffer, 2010a; Mitchell, Miller, Teno, Kiely, 
Davis, & Shaffer, 2010b; van der Steen, Mitchell, Frijters, Kruse, & Ribbe, 2007). 
Nonetheless, prior work suggests that the perception of prognosis may be a more important 
driver of end-of-life care (Cook et al., 2003; Mitchell et al., 2009; van der Steen, Helton, & 
Ribbe, 2009a; Weeks et al., 1998). The primary decision-makers in advanced dementia are 
proxies, but little is known about their perception of the remaining lifetime of the patient they 
are responsible for. Therefore, we asked the following specific research question in study 1: 
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Does proxy’s perception of prognosis of the patient with advanced dementia play a role in 
high-quality decision-making and care?  
The specific objectives of study 1 were to: 1. determine the accuracy of proxies’ 
prognostic estimates, 2. identify factors associated with their prognostic estimates, and 3. 
examine the association between proxy perceived prognosis and whether residents 
experienced any of the following interventions: hospital transfers, parenteral therapy, tube 
feeding, venipunctures, and bladder catheterizations. In addressing these objectives, study 1 
explored factors (see Figure 1, referring to contexts or processes) that influence proxies’ 
understanding that a patient may have less than 6 months to live and evaluated whether this 
understanding is associated with the receipt of less burdensome interventions (see Figure 1, 
outcomes of decision-makers and patients).  
2.1.2. Study 2: How do brief decision support tools tailored to various decision-
makers relate to high-quality decision-making? 
Antibiotics and artificial hydration may be of limited clinical benefit in advanced 
dementia (Givens et al., 2010; Mitchell et al., 2014; H. R. W. Pasman et al., 2005; 2006; van 
der Steen et al., 2012; 2014; 2017a). Relatives lack support, physicians report difficulties 
finding adequate language to address end-of-life decisions, and there is no data on the 
experience of professional guardians making end-of-life decisions (Engel et al., 2006; Givens 
et al., 2009; Pautex et al., 2013; You et al., 2015). The few existing decision support tools in 
advanced dementia are primarily videos that are tailored to only relative decision-makers and 
difficult to implement in nursing homes (Einterz et al., 2014; Hanson et al., 2011; 2017; 
Mitchell et al., 2001; Snyder et al., 2013; Volandes, Barry, Chang, & Paasche-Orlow, 2009a; 
Volandes, Paasche-Orlow, Barry, Gillick, Minaker, et al., 2009b). Study 2 addressed this gap 
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by developing brief decision support tools (two-page, pocket-sized brochures) tailored to 
various decision-makers on antibiotics for pneumonia and artificial hydration in advanced 
dementia. Study 2 was guided by the following specific research question: Can brief decision 
support tools promote high-quality decision-making in various decision-makers?  
The specific objectives of study 2 were to test whether the decision support tools 
impact 1. decisional conflict, 2. knowledge, and 3. preferences about the use of antibiotics 
and artificial hydration in advanced dementia. In addressing these objectives, study 2 
evaluated whether a brief and targeted decision-support tool (see Figure 1, processes) would 
result in reduced decisional conflict, increased knowledge among various decision-makers 
and in a shift in preferences to forego the use of burdensome treatments (see Figure 1, 
outcomes of decision-makers). 
2.1.3. Study 3: When reducing burden may mean choosing death: what are 
perceptions of various decision-makers about controversial end-of-life 
practices? 
Patients with advanced dementia have profound deficits and experience burdensome 
complications that may cause discomfort and result in a poor quality of life (Hendriks et al., 
2014; Mitchell et al., 2009; van der Steen, Deliens, Koopmans, & Onwuteaka-Philipsen, 
2016). Assisted dying and continuous deep sedation until death are controversial end-of-life 
practices that may be used as a last resort to avoid a poor quality of life and death with 
advance dementia (E. J. Emanuel et al., 2016; Miccinesi et al., 2006; Ziegler et al., 2018). 
Little is known about the perceptions of key decision-makers about these practices for 
patients with advanced dementia. In order to advance our understanding in this regard, we 
asked the following specific research question: Do key decision-makers perceive assisted 
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dying and continuous deep sedation until death as a valid end-of-life option in advanced 
dementia?   
The specific objectives of study 3 were to: 1. describe physician and proxy 
perceptions about the use of assisted dying and continuous deep sedation in advanced 
dementia, and 2. compare their perceptions. In addressing these objectives, study 3 explored 
whether physicians and proxies agree with the use of controversial end-of-life practices 
among patients with advanced dementia (see Figure 1, contexts), and whether proxies are 
more inclined to agree with these practices than physicians. 
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3. Study 1: Proxy Perception of Prognosis and Treatment Decisions 
 
Perception of Prognosis Among Proxies of Nursing Home Residents 
with Advanced Dementia1 
 
3.1. Introduction 
More than 5 million Americans have been diagnosed with Alzheimer’s disease; a 
number projected to increase to 13.8 million by 2050 (Hebert, Weuve, Scherr, & Evans, 
2013). Alzheimer’s disease is the sixth most common cause of death in the United States 
(Kochanek, Murphy, Xu, & Tejada-Vera, 2016). Patients with advanced dementia commonly 
experience burdensome interventions that may be of limited benefit and do not promote 
comfort (Gozalo et al., 2011; Meier et al., 2001; Mitchell et al., 2003; 2009; 2014; Mitchell, 
Morris, Park, & Fries, 2004c; Morrison & Siu, 2000b). 
Prognostication influences end-of-life care. The U.S. Medicare Hospice benefit 
requires an estimated life expectancy of 6 months,(The National Hospice Organization, 1996) 
although the prognostic accuracy of hospice guidelines for dementia patients may be little 
better than chance (Mitchell, Miller, Teno, Kiely, Davis, & Shaffer, 2010b). Rigorously 
derived mortality risk scores for this population are only moderately accurate in predicting 6-
month survival (Mitchell, Kiely, Hamel, Park, Morris, et al., 2004b; Mitchell, Miller, Teno, 
Davis, & Shaffer, 2010a; Mitchell, Miller, Teno, Kiely, Davis, & Shaffer, 2010b; van der 
Steen et al., 2007). Nonetheless, prior work suggests that the perception of prognosis is an 
important driver of end-of-life care (Cook et al., 2003; Mitchell et al., 2009; van der Steen, 
                                                
1 A similar version of this chapter has been accepted for publication in the Journal of the American Medical 
Association Internal Medicine (JAMA IM) (Loizeau, Shaffer, Habtemariam, Hanson, Volandes, & Mitchell). 
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Helton, & Ribbe, 2009a; Weeks et al., 1998). Our group found that nursing home (NH) 
residents with advanced dementia whose proxies perceived they had less than 6 months to 
live, were less likely to get tube fed, hospitalized, or receive parenteral therapy in their last 
180 days of life (Mitchell et al., 2009). However, this retrospective analysis was limited to a 
small decedent cohort, and did not examine factors influencing prognostic perceptions. 
Proxies of patients with advanced cancer and critical illness report basing their prognostic 
perceptions on factors such as the need to remain hopeful, religious beliefs, and patient 
attributes (i.e., fortitude) (Boyd et al., 2010; Chiarchiaro, Buddadhumaruk, Arnold, & White, 
2015; D. B. White et al., 2016a). 
To better understand proxies’ perceptions of prognosis and their role in the care of 
NH residents with advanced dementia, we combined data from 2 studies conducted by our 
group: the Study of Pathogen Resistance and Exposure to Antimicrobials in Dementia 
(SPREAD);(Mitchell et al., 2013; 2014) and the Educational Video to Improve Nursing home 
Care in End-stage dementia (EVINCE) trial (Mitchell et al., 2017). In both studies, proxies of 
NH residents with advanced dementia were prospectively asked every 3 months (up to 12 
months) how long they felt the resident had to live. The objectives were to: (1) determine the 
accuracy of proxies’ prognostic estimates, (2) identify factors associated with their prognostic 
estimates, and (3) examine the association between proxies’ perceived prognosis and the 
residents’ receipt of potentially burdensome interventions. 
3.2. Methods  
Data Sources 
Data were leveraged from 2 studies with identically defined populations and data 
collection methods for the variables used in this study: (1) SPREAD: Study of Pathogen 
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Resistance and Exposure to Antimicrobials in Dementia;(Mitchell et al., 2013; 2014) and (2) 
EVINCE: Educational Video to Improve Nursing home Care in End-stage dementia (Mitchell 
et al., 2017). The SPREAD study was a prospective cohort study conducted from September 
2009 through November 2012 in which 362 NH residents with advanced dementia were 
followed in 35 Boston area facilities for 12 months to describe infection management. The 
EVINCE study was a cluster randomized clinical trial conducted in 62 Boston area facilities 
(intervention, N=31; control, N=31) conducted from March 2013 to July 2017. Proxies of NH 
residents with advanced dementia in intervention facilities (N=212) were exposed to an 
advance care planning video whereas those in the control facilities (N=190) experienced 
usual care. Residents were followed for 12 months. Observational data from the intervention 
and control arms were combined for this study.  
Hebrew SeniorLife Institutional Review Board approved the conduct of both studies. 
Proxies provided informed consent for the residents’ and their own participation. They were 
not compensated. 
Study Population 
Recruitment procedures were the same in both studies. Resident eligibility criteria 
included: (1) age 65 years or older, (2) dementia (any type), (3) Global Deterioration Scale 
(GDS) score of 7 (from nurse; range, 1-7; higher scores indicate worse dementia),(Reisberg 
et al., 1982)
 
(4) available English-speaking proxy, and (5) NH stay longer than 90 days. A 
GDS score of 7 is characterized by profound memory deficits (cannot recognize family), 
verbal ability of less than 5 words, incontinence, and non ambulatory status. Every 3 months, 
research assistants (RAs) asked nurses on each NH unit to identify eligible residents. 
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Dementia diagnosis, age, and proxy availability were confirmed by medical chart review. 
Proxies were the residents’ formally or informally designated medical decision-makers. 
Data Elements 
All variables were collected and defined similarly in both studies, unless otherwise 
stated. Residents’ charts were abstracted and proxies were interviewed by RAs at baseline 
and quarterly thereafter for up to 12 months. If the resident died, the medical chart was 
reviewed within 14 days of death. Proxy interviews were conducted by telephone except for 
in-person baseline interviews in EVINCE.  
This study focused on the following question asked at all proxy interviews: “In your 
opinion, how close do you feel [resident] is to the end of her/his life?”, with the following 
response options: (1) less than 1 month, (2) 1 to 6 months, (3) 7 to 12 months, (4) longer than 
12 months, and (5) do not know or refused.  
Two other outcomes were examined; death and use of burdensome interventions. The 
RAs contacted nursing units bimonthly to determine if any residents had died, and if so the 
date of death. At each assessment, the following potentially burdensome interventions 
experienced by residents since the prior assessment were abstracted from their charts: 
hospital transfers (hospitalizations or emergency room visits), parenteral therapy for 
hydration or medication administration, new feeding tube insertion, venipunctures, and 
bladder catheterizations to work-up suspected urinary tract infections (only available in 
SPREAD). We selected these interventions as they were potential sources of discomfort in 
frail older persons,(Morrison et al., 1998) and generally do not reflect comfort-focused care.  
Other variables were used to describe residents and proxies, and included as 
covariates (Boyd et al., 2010; Chiarchiaro et al., 2015; Cook et al., 2003; Mitchell et al., 
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2009; van der Steen, Helton, & Ribbe, 2009a; Weeks et al., 1998; D. B. White et al., 2016a). 
Baseline resident data included: demographics (age, sex, and race (white vs other)), etiology 
of dementia (Alzheimer's disease vs other), common comorbidities (chronic obstructive 
pulmonary disease, congestive heart failure, and diabetes), Test for Severe Impairment (TSI) 
score obtained by direct resident examination (range, 0-24; lower scores indicate greater 
cognitive impairment; dichotomized to equal to vs greater than 0),(Albert & Cohen, 1992) 
and functional status by nurse interview using the Bedford Alzheimer’s Nursing Severity-
Subscale (BANS-S; range, 7-28; higher scores indicate greater functional disability) (Volicer, 
Hurley, Lathi, & Kowall, 1994). At every assessment, it was determined whether the resident 
experienced any of the following new major illnesses since the prior assessment: hip fracture, 
stroke, myocardial infarction, major gastrointestinal bleed, pneumonia, and new diagnosis of 
cancer (other than localized skin cancer).  
Baseline proxy data included: age, sex, years as proxy, and relationship to resident 
(child vs other). At all interviews, proxies were asked whether any NH clinicians had asked 
their opinion about the resident’s goal of care (yes/no).  
Analysis 
Analyses were conducted using SAS statistical software (version 9.4, SAS Institute). 
Main results were generated for the combined cohorts and presented for each study separately 
in Appendices A1, A2, and A3. Means (SDs), and frequencies were used to describe 
continuous and categorical variables, respectively.  
Cumulative incidence of death was displayed graphically and compared between 
SPREAD and EVINCE using survival analysis. For residents who died, survival time was 
calculated as the number of days between the date of baseline proxy interview and date of 
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resident death. For all analyses examining survival as an outcome, residents who survived the 
follow-up period were censored at 12 months and those lost to follow-up were censored at the 
last known follow-up date. 
Cox proportional hazards regression examined the accuracy of proxies’ prognostic 
estimates (independent variable) as ascertained from all interviews and analyzed as time-
varying variables. A prognostic estimate later than 12 months was the referent category. The 
model examined the association between the prognostic estimates at a particular interview 
date and the risk of the resident dying given that the resident had survived up until that point. 
Because response options did not include prognostic estimates between 6 and 7 months, 
actual survival times during that interval were rounded up or down. Robust standard errors 
accounted for clustering at the facility-level. Adjusted hazard ratios (AHRs) and 95% 
confidence intervals (CIs) were computed. A generalized version of the c statistic allowing 
for censored data was calculated as a measure of the model’s overall accuracy (range 0.5-1, 
higher scores indicate greater accuracy) (Mayo Foundation for Medical Education and 
Research). A sensitivity analysis excluded proxies in the EVINCE intervention group because 
the video could have influenced the accuracy of their prognostic estimates.  
Logistic regression was used to identify resident and proxy characteristics 
(independent variables) associated with a proxy prognostic estimate of less than 6 months 
(outcome). The prognosis variable was dichotomized because the proportion of interviews at 
which proxies estimated prognosis to be less than 1 month and 1 to 6 months were too small 
to examine as separate categories. Interviews at which the proxy responded “do not know” or 
refused to answer were excluded. The analysis was conducted at the level of assessment 
intervals. Independent variables considered a priori to be possibly associated with 
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prognostication, (Boyd et al., 2010; Chiarchiaro et al., 2015; Mitchell et al., 2009; D. B. 
White et al., 2016a) included; resident demographics (age [dichotomized at median], sex, 
race), dementia type, comorbidities, TSI, BANS-S, hospital transfer in prior 3 months, proxy 
demographics (age (dichotomized at median), gender), proxy relationship to resident, and 
goals of care discussions. Proxy prognostic estimates and other dynamic independent 
variables (e.g., hospital transfers) were ascertained from each assessment. Static variables 
(e.g., sex) were brought forward from baseline. Bivariable analyses examined the unadjusted 
associations between each independent variable and prognosis at a given assessment interval. 
Variables associated with the outcome at P < .10 in the unadjusted analyses were entered into 
a multivariable model. Generalized estimating equations (GEE) accounted for clustering 
among residents/proxy dyads. Odds ratios (ORs) with 95% CIs were computed.  
Finally, logistic regression was used to examine the association between a proxy 
prognostic estimate of less than 6 months (main independent variable) and the use of any of 
the following burdensome interventions (outcome): hospital transfer, parenteral therapy, new 
feeding tube, venipuncture, and bladder catheterization. The analysis was conducted at the 
level of assessment intervals and excluded assessments with “do not know/refused” responses 
to the prognosis question. Prognosis was derived from the interview conducted at the 
beginning of a given 3-month interval. The outcome was defined as whether the resident 
experienced a burdensome intervention during the 3-month interval following that interview. 
Covariates considered a priori to be possibly associated with intervention use (Cook et al., 
2003; Mitchell et al., 2009; van der Steen, Helton, & Ribbe, 2009a; Weeks et al., 1998) 
included: resident demographics, dementia type, comorbidities, TSI, BANS-S, new major 
illness, proxy demographics, proxy relationship to resident, and goals of care discussions. 
Dynamic covariates were drawn from the assessment that best related the resident’s status 
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during the interval. For example, occurrence of a major illness was ascertained from the 
medical chart review done at the end of the interval, which recorded events during the 
interval. Being asked about goals of care was drawn from the interview at the start of the 
interval. Static variables were brought forward from baseline. Bivariable followed by 
multivariable analyses were conducted as described above and GEE accounted for clustering 
among resident/proxy dyads. Odds ratios with 95% CIs were computed.  
3.3. Results 
Resident and Proxy Characteristics  
 Baseline characteristics were comparable between the 2 studies (SPREAD, N=362 
dyads; EVINCE, N=402 dyads) (Table 1). Resident characteristics of the combined cohort 
(N=764 dyads) included: mean (SD) age, 86.6 (7.3) years; female, 631 (82.6%); and white, 
685 (89.7%). A total of 412 (53.9%) residents had TSI scores equal to 0, and their mean (SD) 
BANS-S score was 20.6 (2.8), indicating severe cognitive and functional impairment, 
respectively. Proxy characteristics were: mean (SD) age, 61.4 (10.6) years; female, 492 
(64.4%); years as proxy, 8.8 (6.3); and child of resident, 489 (64.0%). 
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Table 1. Baseline characteristics of nursing home residents with advanced dementia and their proxies 
Characteristics 
SPREAD and 
EVINCE combined 
(N=764)a 
SPREAD 
(N=362) 
EVINCE 
(N=402) 
Resident    
Age (years), mean ± standard deviation 86.6 ± 7.3 86.5 ± 7.3 86.7 ± 7.4 
   Age > 87 (median) 362 (47.4) 174 (48.1) 188 (46.8) 
Female, % 631 (82.6) 308 (85.1) 323 (80.3) 
White (vs other), % 685 (89.7) 335 (92.5) 350 (87.1) 
Alzheimer’s disease (vs other), % 552 (72.3) 269 (74.3) 283 (70.4) 
Chronic obstructive pulmonary disease, % 90 (11.8) 42 (11.6) 48 (11.9) 
Congestive heart failure, % 120 (15.7) 63 (17.4) 57 (14.2) 
Diabetes, % 146 (19.1) 67 (18.5) 79 (19.7) 
TSI = 0 (vs greater than 0), %b 412 (53.9) 222 (61.3) 190 (47.3) 
BANS-S, mean ± standard deviationc  20.6 ± 2.8 21.2 ± 2.7 20.1 ± 2.8 
   BANS-S > 21 (median) 328 (42.9) 182 (50.3) 146 (36.3) 
Enrolled in hospice  105 (13.7) 31 (8.6) 74 (18.4) 
Died during 12 month follow-up, % 310 (40.6) 135 (37.3) 175 (43.5) 
Proxy    
Age (years), mean ± standard deviationd 61.4 ± 10.6 60.4 ± 10.3 62.3 ± 10.8 
   Age > 61 (median) 348 (45.6) 153 (42.3) 195 (48.5) 
Female, % 492 (64.4) 226 (62.4) 266 (66.2) 
Years as proxy, mean ± standard deviationd 8.8 ± 6.3 8.1 ± 5.7 9.4 ± 6.8 
Child of resident (vs other), % 489 (64.0) 233 (64.4) 256 (63.7) 
Prognostic estimates of resident survival at the 
baseline interviews only, %     
   <1 month 10 (1.3) 3 (0.8) 7 (1.7) 
   1-6 months 75 (9.8) 29 (8.0) 46 (11.4) 
   7-12 months 148 (19.4) 59 (16.3) 89 (22.1) 
   >12 months 477 (62.4) 240 (66.3) 237 (59.0) 
   Don’t know or refused to answer 54 (7.1) 31 (8.6) 23 (5.7) 
aSPREAD = the Study of Pathogen Resistance and Exposure to Antimicrobials in Dementia; EVINCE = the 
Educational Video to Improve Nursing home Care in End-stage dementia.  
bTSI = Test for Severe Impairment, range 0-24, lower scores indicate greater cognitive impairment. 
cBANS-S = Bedford Alzheimer’s Nursing Severity-Subscale, range 7-28, higher scores indicate more 
functional disability. 
dData missing for proxy age (N=10) and years as proxy (N=5). 
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Survival and Accuracy of Proxy Prognostic Estimates 
In the combined cohort, 310 (40.6%) residents died, and 11 (1.4%) were lost to 
follow-up. In SPREAD, 135 (37.3%) residents died and 5 (1.4%) were lost to follow-up. In 
EVINCE, 175 (43.5%) residents died and 6 (1.5%) were lost to follow-up. Six-month 
mortality rates were: combined cohort, 195 (25.5%); SPREAD, 88 (24.3%); and EVINCE, 
107 (26.6%). The Figure 2 shows the cumulative incidences of death for the combined 
cohort, and each cohort separately which did not differ significantly (log rank P = .08).
 
Figure 2. Cumulative incidences of death among 764 nursing home residents with advanced dementia.  
Cumulative incidences of death among nursing home residents with advanced dementia in the Study of 
Pathogen Resistance and Exposure to Antimicrobials in Dementia study (N=362; dotted line) and the 
Educational Video to Improve Nursing Home Care in End-stage dementia study (N=402; dashed line), and two 
studies combined (N=764; solid line).  
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At baseline, proxies’ estimates of the resident prognosis were: less than 1 month, 10 
(1.3%); 1 to 6 months, 75 (9.8%); 7 to 12 months, 148 (19.4%); longer than 12 months, 477 
(62.4%); and do not know/refused, N=54 (7.1%). At all proxy interviews (i.e., baseline and 
follow-up) (2649), proxy prognostic estimates were: less than 1 month, 30 (1.1%); 1 to 6 
months, 279 (10.5%); 7 to 12 months, 664 (25.1%); longer than 12 months, 1553 (58.6%); 
and do not know/refused, 123 (4.6%). In the Cox model, the likelihood of dying was higher 
among residents whose proxies thought they had a shorter prognosis (referent, longer than 12 
months): less than 1 month (AHR, 27.53; 95% CI, 15.81, 47.95); 1 to 6 months (AHR, 4.61; 
95% CI, 3.12, 6.79); 7 to 12 months (AHR, 1.91; 95% CI, 1.38, 2.64); and do not 
know/refused (AHR, 0.92; 95% CI, 0.40, 2.14). The model’s c statistic was 0.67. Results 
were similar when analyzed in the EVINCE cohort with the intervention arm excluded: less 
than 1 month, AHR, 28.77; 95% CI, 13.99, 59.18; 1 to 6 months, AHR, 4.89; 95% CI, 3.10, 
7.71; 7 to 12 months, AHR, 2.05; 95% CI, 1.43, 2.94; and don’t know/refused, AHR, 1.04; 
95% CI, 0.39, 2.78. The c statistic was 0.67.  
Factors Associated with Proxy Prognostication  
The proportion of all interviews (2526) at which proxies stated the resident had less 
than 6 months was 12.2% (309). In unadjusted analyses, variables associated with a proxy 
prognostic estimate of less than 6 months at a P < .10 were: resident age older than 87 years, 
female proxy, and being asked about goals of care (Table 2). In the multivariable model, only 
having been asked about goals of care (adjusted odds ratio [AOR], 1.94; 95% CI, 1.50, 2.52) 
and female proxy (AOR, 1.55; 95% CI, 1.09, 2.20) remained significantly associated with a 
prognostic estimate of less than 6 months.  
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Table 2. Association between characteristics of nursing home residents with advanced dementia and their 
proxies and the proxy's perception that the resident had less than 6 months to livea 
  
Total No. (%) 
of Assessment 
Intervals with 
Characteristica 
(N=2526) 
No. (%) of Assessment 
Intervals in Which Proxy 
Estimated Resident had < 6 
Months to Live (N=309) 
Odds Ratiob for Proxy Perceived 
Prognosis (95% Confidence 
Interval) 
Characteristic 
With 
Characteristic 
Present 
With 
Characteristic 
Absent Unadjusted Adjusted 
Resident       
Age > 87 (median) 1178 (46.6) 164 (6.5) 145 (5.7) 1.34 (0.96, 1.88)c  
Female 2110 (83.5) 248 (9.8) 61 (2.4) 0.78 (0.50, 1.21)  
White 2272 (89.9) 279 (11.1) 30 (1.2) 1.05 (0.56, 1.96)  
Alzheimer’s disease  1813 (71.8) 216 (8.6) 93 (3.7) 0.90 (0.62, 1.31)  
Chronic obstructive 
pulmonary disease 264 (10.5) 43 (1.7) 266 (10.5) 1.46 (0.92, 2.32)  
Congestive heart failure 387 (15.3) 52 (2.1) 257 (10.2) 1.14 (0.71, 1.81)  
Diabetes 454 (18.0) 56 (2.2) 253 (10.0) 1.01 (0.66, 1.56)  
TSI = 0d 1315 (52.1) 165 (6.5) 144 (5.7) 1.06 (0.76, 1.49)  
BANS-S > 21 (median)e  996 (39.4) 129 (5.1) 180 (7.1) 1.12 (0.80, 1.56)  
Any hospital transfer in 
prior 3 monthsf 100 (4.0) 17 (0.7) 292 (11.6) 1.50 (0.86, 2.60)  
Proxy       
Age > 61 (median)g 1186 (47.4) 158 (6.3) 149 (6.0) 1.20 (0.86, 1.69)  
Female 1613 (63.9) 224 (8.9) 85 (3.4) 1.57 (1.10, 2.24)c 1.55 (1.09, 2.20) 
Child of resident 1565 (62.0) 200 (7.9) 109 (4.3) 1.15 (0.80, 1.65)  
Asked their opinion 
about goals of care by a 
nursing home clinician 
1126 (44.6) 183 (7.2) 126 (5.0) 1.96 (1.52, 2.54)c 1.94 (1.50, 2.52) 
aAnalyses were done at the level of assessment intervals, which included all baseline and follow-up 
resident/proxy assessment intervals (N=2526). Resident chart reviews and proxy interviews were done at 
baseline and quarterly for up to 12 months. Static variables were brought forward from baseline. Proxy’s 
perception of prognosis and other dynamic variables (e.g., goals of care discussion, hospital transfers) were 
ascertained from each assessment period. Proxies stated the resident had less than 6 months to live at 12.2% of 
all baseline and follow-up assessment intervals (309 of 2526).  
bUnadjusted and adjusted odds ratio accounted for clustering among resident/proxy dyads using generalized 
estimating equations. 
cVariables that were significant at P < 0.10 in bivariable analyses and entered into the multivariable model.  
dTSI = Test for Severe Impairment, range 0-24, lower scores indicate greater cognitive impairment. 
eBANS-S = Bedford Alzheimer’s Nursing Severity-Subscale, range 7-28, higher scores indicate greater 
functional disability. 
fHospital transfer included hospitalization or emergency room visit.  
gAge missing for 24 proxies. 
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Table 3. Association between proxy perception of prognosis and use of burdensome interventionsa among 
nursing home residents with advanced dementia 
  
Total No. (%) 
of Assessment 
Intervals with 
Characteristicb 
(N=2031) 
No. (%) of Assessment 
Intervals in Which Resident 
had Any Burdensome 
Interventions (N=1097) 
Likelihood of a Burdensome 
Intervention ORc (95% Confidence 
Interval) 
Characteristic 
With 
Characteristic 
Present 
With 
Characteristic 
Absent Unadjusted Adjusted 
Proxy Estimated 
Resident had < 6 
Months to Live 
251 (12.4) 89 (4.4) 1008 (49.6) 0.47 (0.35, 0.62)d 0.46 (0.34, 0.62) 
Resident Covariates      
Age > 87 (median) 954 (47.0) 490 (24.1) 607 (29.9) 0.81 (0.64, 1.02)d 0.77 (0.61, 0.97) 
Female 1691 (83.3) 917 (45.2) 180 (8.9) 1.13 (0.83, 1.52)  
White 1837 (90.5) 970 (47.8) 127 (6.3) 0.58 (0.40, 0.86)d  
Alzheimer’s disease  1472 (72.5) 781 (38.5) 316 (15.6) 0.89 (0.69, 1.14)  
Chronic obstructive 
pulmonary disease 217 (10.7) 120 (5.9) 977 (48.1) 1.00 (0.69, 1.44)  
Congestive heart failure 318 (15.7) 203 (10.0) 894 (44.0) 1.63 (1.19, 2.22)d 1.63 (1.19, 2.24) 
Diabetes 357 (17.6) 243 (12.0) 854 (42.1) 1.94 (1.41, 2.67)d 1.91 (1.39, 2.63) 
TSI = 0e 1053 (51.9) 501 (24.7) 596 (29.4) 0.57 (0.46, 0.72)d 0.66 (0.52, 0.86) 
BANS-S > 21 (median)f 808 (39.8) 373 (18.4) 724 (35.7) 0.58 (0.46, 0.74)d 0.68 (0.53, 0.88) 
Any new major illness 
in prior 3 monthsg 109 (5.4) 82 (4.0) 1015 (50.0) 2.59 (1.70, 3.96)
d 2.83 (1.84, 4.35) 
Proxy Covariates      
Age > 61 (median)h 941 (46.3) 481 (23.7) 606 (29.8) 0.78 (0.62, 0.98)d  
Female 1288 (63.4) 671 (33.0) 426 (21.0) 0.86 (0.68, 1.08)  
Child of resident 1268 (62.4) 709 (34.9) 388 (19.1) 1.22 (0.97, 1.55)d  
Asked their opinion 
about goals of care by a 
nursing home clinician 
953 (46.9) 501 (24.7) 596 (29.4) 0.88 (0.74, 1.04)  
aBurdensome interventions included any of the following: hospital transfer (hospitalization or emergency room 
visits), parenteral therapy, new feeding tube insertion, venipuncture, and bladder catheterizations. 
bAnalyses were done at the level of assessment intervals, which included baseline and follow-up resident/proxy 
assessment intervals (N=2031). Proxy prognosis was taken from the interview done at the start of the interval. 
The use of burdensome interventions reflected the residents experience during the 3-month interval following 
that interview. Dynamic covariates were drawn from the assessment that best reflected the resident’s status 
during the interval of interest (e.g., any new major illness). Static variables were brought forward from baseline. 
cUnadjusted and adjusted odds ratio accounted for clustering among resident/proxy dyads using generalized 
estimating equations. 
dVariables that were significant at P < 0.10 in bivariable analyses and entered into the multivariable model.  
eTSI = Test for Severe Impairment, range 0-24, lower scores indicate greater cognitive impairment. 
fBANS-S = Bedford Alzheimer’s Nursing Severity-Subscale, range 7-28, higher scores indicate more disability. 
gAny new major illness included hip fracture, stroke, myocardial infarction, major gastrointestinal bleed, 
pneumonia, and/or new diagnosis of cancer (other than localized skin cancer).  
hAge missing for 18 proxies. 
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Use of Burdensome Interventions 
There were 2031 resident-assessment intervals available to examine the use of 
burdensome interventions over the follow-up period. The proportion of intervals during 
which residents experienced burdensome interventions were: hospital transfer, 68 (3.3%); 
parenteral therapy, 49 (2.4%); new feeding tube, 3 (0.1%); venipuncture, 1048 (51.6%); 
bladder catheterizations, 157 (7.7%); and any intervention, 1097 (54.0%). In unadjusted 
analyses, factors associated with a lower likelihood of any burdensome intervention use at P 
< 0.10 included: proxy prognosis of less than 6 months, resident age older than 87 years, 
white resident, TSI equal to 0, BANS-S greater than 21, proxy age older than 61 years, and 
child of resident (Table 3). Congestive heart failure, diabetes, and any new major illness were 
associated with a greater likelihood of receiving a burdensome intervention. After 
multivariable adjustment, a prognostic estimate of less than 6 months remained significantly 
associated with a lower likelihood of the resident receiving any burdensome interventions 
(AOR, 0.46; 95% CI, 0.34, 0.62).  
3.4. Discussion 
In this study, proxies of NH residents with advanced dementia predicted how long the 
resident would live with moderate accuracy. Having been asked about their opinion about the 
goals of care was the factor most strongly associated with the proxies’ perception that the 
resident had less than 6 months to live. Residents were significantly less likely to experience 
burdensome interventions when their proxies perceived they would die within 6 months.  
The accuracy of the proxy’s prognostic estimates was modest, but remarkably 
identical to the empirically derived Advanced Dementia Prognostic Tool (c statistic, 0.67), 
and better than hospice guidelines for dementia (c statistic, 0.55) (Mitchell, Miller, Teno, 
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Kiely, Davis, & Shaffer, 2010b). Prognostic estimates of proxies of patients in intensive care 
units are reportedly somewhat more accurate (c statistic, 0.74),(D. B. White et al., 2016a) 
perhaps because it is easier to recognize impending death in the context of critical illness. We 
found a minority of proxies believed the resident would die within 6 months, and that they 
underestimated mortality; 40.6% of residents died after 12 months but at baseline only 30.5% 
of proxies perceived the resident would die in 12 months. An overly optimistic perception of 
prognosis is a consistent finding among proxies, patients, and clinicians in the context of 
other serious illnesses (Fried, Bradley, & O'Leary, 2006; Weeks et al., 1998; D. B. White et 
al., 2016a; N. White, Reid, Harris, Harries, & Stone, 2016b). 
Having been asked their opinion about the goals of care by NH clinicians was most 
strongly associated with proxies’ perception that the resident had less than 6 months to live. 
Given that the question referred to a time period before the proxy interview, renders it less 
likely the association was owing to proxies seeking out goals of care discussions as a 
consequence of believing the resident may die soon. Although we did not ascertain the 
contents of these conversations, research from the critical care setting found that clinicians 
make prognostic statements of some nature in most discussions about goals of care (D. B. 
White, Engelberg, Wenrich, Lo, & Curtis, 2007). 
This study supports and furthers research suggesting that patients whose proxies 
believe they are close to the end-of-life are more likely to opt for comfort-focused 
care,(Mitchell et al., 2017) and receive fewer burdensome interventions (Cook et al., 2003; 
Mitchell et al., 2009; van der Steen, Helton, & Ribbe, 2009a; Weeks et al., 1998). A cross-
sectional analysis of baseline EVINCE data found that proxies who perceived that the 
resident had a life expectancy of less than 6 months were significantly more likely to prefer a 
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level of care that only included treatments to reduce suffering vs one that included potentially 
life-prolonging but uncomfortable interventions (AOR, 12.25; 95% CI, 4.04, 37.08) (Mitchell 
et al., 2017). The interventions considered potentially burdensome in this study are not 
indicative of comfort-focused care. Even venipunctures and bladder catheterizations, which 
may be considered relatively benign, can be a source of discomfort in these very frail 
residents and generally are not undertaken when the goal of care is solely comfort (Morrison 
et al., 1998). 
Several limitations of this report deserve comment. First, the study was limited to a 
primarily white cohort in Boston area NHs, and thus findings may not be generalizable to 
other regions or populations. Second, proxies selected their prognostic estimates from 
categories of expected survival. Alternative approaches, such as estimating the probability of 
surviving a given time frame (probability approach), asking about life expectancy in a more 
open-ended fashion (temporal approach) or the “surprise question” method, may yield 
different prognostic accuracies (Perez-Cruz et al., 2014; N. White et al., 2016b; N. White, 
Kupeli, Vickerstaff, & Stone, 2017). Third, we could not assess the accuracy of the proxies’ 
reports about being asked about goals of care or which aspects of these discussions may have 
influenced their prognostic estimates. It is likely that factors not captured in the dataset 
impacted those perceptions,(Boyd et al., 2010; Chiarchiaro et al., 2015; D. B. White et al., 
2016a) but require a qualitative approach to elucidate.  
This report demonstrates that proxies are moderately accurate in estimating how long 
NH residents with advanced dementia will live. Regardless of accuracy, the proxy’s 
perception that the resident may die within 6 months was associated with the use of fewer 
burdensome interventions. Goals of care discussions with clinicians may be important for 
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proxies to gain that perception. In advanced dementia, in which highly accurate 
prognostication can be elusive, an understanding of the terminal nature of this condition may 
be pertinent to promoting a comfort-focused approach to care. 
 
  
STUDY 1 
 
44 
 
STUDY 2 
 
45 
4. Study 2: Decision Support Tools for Treatment Decisions 
Fact Box Decision Support Tools for Antibiotics for Pneumonia 
and Artificial Hydration in Advanced Dementia: a Randomized 
Controlled Trial 2 
 
4.1. Introduction 
Advanced dementia is associated with a high mortality risk and characterized by 
repeated pneumonia episodes and reduced oral intake (Mitchell et al., 2009; van der Steen et 
al., 2006). Consequently, patients commonly receive antibiotics and artificial hydration, but 
these interventions can be burdensome and have questionable benefit at the end-of-life 
(Givens et al., 2010; Mitchell et al., 2014; H. R. W. Pasman et al., 2005; 2006; van der Steen 
et al., 2012; 2014; 2017a). 
The majority of surrogate decision-makers for advanced dementia patients are family 
members. These family members report lack of adequate decision support from health care 
providers,(Engel et al., 2006; Givens et al., 2009) which may lead to uninformed treatment 
decisions that do not align with goals of care (Mitchell et al., 2009; 2014; 2017). Prior 
research shows that when families receive provider counseling, advanced dementia patients 
are less likely to undergo burdensome interventions in their last months of life (Mitchell et 
al., 2009). In the absence of relatives, treatment decisions are made by professional 
guardians, but data on their experience making choices about end-of-life care is lacking. 
                                                
2 A similar version of this chapter is under revision at Age & Ageing (Loizeau, Theill, Cohen, Eicher, Mitchell, 
Meier, McDowell, Martin, & Riese). 
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Decision support tools improve medical decision-making by improving knowledge 
and reducing decisional conflict (Einterz et al., 2014; Hanson et al., 2011; Mitchell et al., 
2001; Snyder et al., 2013; Volandes, Barry, Chang, & Paasche-Orlow, 2009a). The few 
decision support tools designed specifically for proxies of patients with advanced dementia 
promote preferences for more comfort-focused care (Einterz et al., 2014; Hanson et al., 2011; 
2017; Volandes, Barry, Chang, & Paasche-Orlow, 2009a; Volandes, Paasche-Orlow, Barry, 
Gillick, Minaker, et al., 2009b). A prior randomized controlled trial (RCT) showed that a 20-
minute, paper-print decision support tool about feeding options in advanced dementia 
reduced surrogates’ decisional conflict, improved their knowledge, fostered communication 
with providers, and resulted in residents receiving increased eating assistance (Hanson et al., 
2011). While these tools have been found to be effective, they are tailored to only a single 
group of decision makers (Einterz et al., 2014; Hanson et al., 2011; 2017; Mitchell et al., 
2001; Snyder et al., 2013; Volandes, Barry, Chang, & Paasche-Orlow, 2009a; Volandes, 
Paasche-Orlow, Barry, Gillick, Minaker, et al., 2009b). 
Fact Boxes are short, inexpensive, paper-based decision support tools that are tailored 
for a variety of decision-makers. Using simple, understandable language, they present 
balanced information on the benefits and harms of receiving versus not receiving a treatment 
(McDowell, Rebitschek, Gigerenzer, & Wegwarth, 2016; Schwartz, Woloshin, & Welch, 
2009). This report presents the findings of a RCT of Fact Boxes developed for decisions 
related to the use of antibiotics for pneumonia and artificial hydration in advanced dementia; 
the DEMentia FACT box (DEMFACT) trial. The trial was conducted in the Swiss-German 
region of Switzerland. Physicians, relatives of dementia patients, and professional guardians 
were randomized to either receive (intervention) or not receive (control) the Fact Boxes. All 
participants were asked to make treatment decisions about antibiotics and artificial hydration 
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for advanced dementia patients based on hypothetical scenarios. The primary outcome was 
decisional conflict about treatment decisions. Secondary outcomes included knowledge about 
treatments, and preferences to forego antibiotics and artificial hydration.  
4.2. Methods 
Design 
DEMFACT was a RCT conducted in the Swiss-German region of Switzerland. 
Participant recruitment began in April, 2016 and data collection was completed in October, 
2016. The ethics commission of the canton of Zurich approved the study (KEK-ZH-No. 
2015-0626). All participants provided written informed consent. 
Recruitment and Randomization 
To understand the impact of the DEMFACT intervention on various decision-makers, 
participants included physicians, relatives of dementia patients, and professional guardians 
who were potentially responsible for the care of advanced dementia patients. Physicians were 
identified from the mailing lists of the Swiss Association for Palliative Medicine, Care and 
Support, and the Swiss Geriatric Medicine Society. Relatives of dementia patients were 
identified through the Alzheimer Association of the canton of Zurich. Professional guardians 
were identified from the Swiss Association of Professional Guardians mailing list. To solicit 
participation, all physicians and professional guardians on the aforementioned mailing lists 
were sent emails in April and May of 2016, while all members of the Alzheimer Association 
were mailed letters in April of 2016. The emails and letters included instructions on how to 
contact our team if the recipient wished to participate. Participants had to be proficient in 
German to enroll. Individuals opting to enroll were randomly assigned by an independent 
statistician to either the intervention or control arm using a computer generated-
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randomization list with a 1:1 allocation ratio. Randomization was stratified by participant 
subgroups (i.e., physicians, relatives, and professional guardians). Once randomized, 
participants received information about their arm assignment by mail and were asked to 
return a signed consent form to the research team.  
Intervention 
The intervention consisted of two Fact Box decision support tools for advanced 
dementia: one for decisions about antibiotic use and another for artificial hydration use 
(Center for Gerontology, University of Zurich, 2016). The structure of these tools were based 
on guidelines for developing Fact Boxes and incorporated guidelines from the International 
Patient Decision Aid Standards (Elwyn et al., 2006; McDowell et al., 2016; Schwartz et al., 
2009). Their content was selected based on literature reviews conducted by two independent 
reviewers (AJL and SM) on the use of antibiotics and artificial hydration in advanced 
dementia (H. R. W. Pasman et al., 2005; 2006; van der Maaden et al., 2016; van der Steen et 
al., 2012). Following an iterative process, the drafts of the tools were then reviewed by the 
head of a dementia ward (FR), two specialists on risk communication (MMc and colleague), 
and eight experts on aging research (NT, SE, MMa, and colleagues). The final versions are 
shown in Appendices B1 and B2. 
The Fact Box on antibiotics is a two-page, pocket-sized brochure that presents the 
typical features of pneumonia, the benefits and harms of using antibiotics, and alternative 
treatment options. The Fact Box on artificial hydration is a similar format and describes the 
administration, benefits, harms, and alternatives to artificial hydration for suspected 
dehydration or reduced oral intake.  
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Data Collection and Elements 
Data collection was procedurally identical across participant subgroups, unless 
otherwise stated. Data were collected using two similar written questionnaires (sent and 
returned by mail; approximately 60 minutes to complete) completed by participants at the 
time of initial recruitment and one-month follow-up.  
Participants in the intervention arm were mailed the Fact Boxes along with the one-
month follow-up questionnaire. Participants in the control arm did not receive any additional 
information along with the one-month follow-up questionnaire. 
The baseline and follow-up questionnaires first described two hypothetical scenarios 
(same scenarios at each time period). One scenario presented an advanced dementia patient 
with pneumonia based on a case by Mitchell et al (2015). The second scenario consisted of an 
advanced dementia patient with insufficient fluid intake based on a case by Garbiel and 
Tschanz (2015). After reading each scenario, participants were subsequently asked the same 
series of questions pertaining to the use of antibiotics or artificial hydration. Comfort with 
decision-making was assessed using a validated German version of the Decisional Conflict 
Scale (DCS-D; 5-point Likert scale of 16 items; range 0-100, higher scores indicate greater 
conflict) (Buchholz, Hölzel, Kriston, Simon, & Härter, 2011; O'Connor, 1995). Participants’ 
knowledge was ascertained using 7-item true-false scales specific to each treatment (scored, 
1=true, 0=false/don’t know; range 0-7, higher scores indicate greater knowledge) (the scales 
are shown in Appendices B3 and B4). Preferences to use antibiotics and artificial hydration 
were measured using single question with response options including; ‘use’, ‘forego’, or 
‘undecided’.  
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Other participant data collected only at baseline included: demographics (age, gender, 
and religion (Protestant, Catholic, no religion, and other)), the educational level of relatives 
of dementia patients (≥ high school versus other), and whether participants had previously 
made a decision about the use of antibiotics and/or artificial hydration for a person with 
dementia. Professional guardians reported whether they had previously served as a legal 
guardian for a person with dementia.  
In the intervention arm only, participants were asked to rate the helpfulness of the 
Fact Boxes (‘helpful’, ‘somewhat helpful’, ‘neither helpful nor unhelpful’, ‘somewhat 
unhelpful’, and ‘unhelpful’); appropriateness of both the content and layout (‘very good’, 
‘good’, ‘fair’, ‘bad’, and ‘very bad’); and amount of information (‘too much’, ‘too little’, and 
‘exactly right’). The physicians were asked if they agree to using Fact Boxes while 
communicating with patients/decision-makers (‘agree’, ‘somewhat agree’, ‘neither agree nor 
disagree’, ‘somewhat disagree’, and ‘disagree’).  
Statistical Analysis 
The trial’s primary outcome was the reduction in DCS-D scores for decisions on the 
use of antibiotics and artificial hydration. Secondary outcomes included knowledge about 
each treatment, and preferences to forego the treatments. Analyses were performed using R 
Version 3.3.2 (Boston, MA). Means with standard deviations (SDs) and frequencies 
described continuous and categorical variables, respectively. Outcomes were compared 
between trial arms at baseline using independent t-tests for continuous variables and chi-
squared tests for categorical variables. 
Similar approaches were used to analyze outcomes for decisions related to antibiotic 
and artificial hydration use. Linear mixed-effects models (lme4 package) were used to 
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examine the outcomes of DCS-D and knowledge. To capture changes between the one-month 
follow-up and baseline measures in the intervention relative to the control arm, these models 
included a term specifying the interaction between trial arms (intervention versus control) and 
assessments (one-month follow-up versus baseline). Random effects were used to account for 
repeated measurements among individuals. Unstandardized beta (b) and 95% confidence 
intervals (CIs) were computed. Logistic regression models compared changes in treatment 
preferences (‘forego’ versus ‘use’ or ‘undecided’) between the one-month follow-up and 
baseline in the intervention relative to the control arm. Odds ratios (ORs) and 95% CIs were 
computed. Models were generated for all participants and also stratified by participant 
subgroups. 
A minimum sample size of 198 was calculated to provide at least 80% power to detect 
an effect of 0.1 between trial arms for the primary outcome. The sample size calculation 
assumed two repeated measurements and a 5% type I error rate. A conservative effect size 
was selected because the impact of decision aids on decisional conflict is highly variable 
(Hanson et al., 2011; Mitchell et al., 2001; Snyder et al., 2013; Volandes, Barry, Chang, & 
Paasche-Orlow, 2009a). 
4.3. Results 
Enrollment and Participant Characteristics  
Of the 3860 individuals approached for participation, 254 (6.6%) contacted the 
research team indicating their willingness to participate, and all were eligible for recruitment 
(the CONSORT flow diagram of participant subgroups is shown in Appendix B5). During the 
course of the study, fifteen participants (intervention, N=10; control, N=5) stopped 
responding to e-mails and/or phone calls, and seven participants withdrew (intervention, 
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N=4; control, N=3). The final analytic sample completing both baseline and follow-up 
assessments included 232 participants (intervention, N=114; control, N=118) consisting of 
the following subgroups: intervention (physicians, N=30 (26.3%); relatives, N=51 (44.7%); 
and professional guardians, N=33 (28.9%)), and control (physicians, N=34 (28.8%); 
relatives, N=49 (41.5%); and professional guardians, N=35 (29.7%)). 
Table 4. Baseline characteristics of participants (N=232) by trial arm 
Characteristics 
Intervention 
(N=114) 
Control 
(N=118) 
No. (%) No. (%) 
Participants   
Physicians 30 (26.3) 34 (28.8) 
Relatives 51 (44.7) 49 (41.5) 
Professional guardians 33 (28.9) 35 (29.7) 
Age, year, mean ± standard deviationa 56.1 ± 14.1 55.0 ± 13.5 
range 26–87 27–87 
Femalea 68 (59.6) 77 (65.3) 
Religiona   
Protestant 52 (45.6) 42 (35.6) 
Catholic 20 (17.5) 38 (32.2) 
no religion 27 (23.7) 21 (17.8) 
other 14 (12.3) 15 (12.7) 
Education of relativea   
≥ high school 50 (98.0) 45 (91.8) 
Professional guardian's experience with dementiab 29 (87.9) 33 (94.3) 
Prior decisions ona,c   
antibiotics 41 (36.0) 48 (40.7) 
artificial hydration 39 (34.2) 42 (35.6) 
aTotal number of missing values by demographic characteristics: age (N=1), 
female (N=1), religion (N=3), education of relative (N=1), and prior decisions on 
antibiotics (N=2) and artificial hydration (N=2). 
bProfessional guardians reported whether they had previously served as a legal 
guardian for a person with dementia. 
cParticipants reported whether they had previously made a decision about the use 
of antibiotics and/or artificial hydration for a person with dementia. 
 
Baseline characteristics were similar between trial arms (Table 4). Participants’ mean 
age was 55.6 years (range 26-87) and 62.8% (N=145/231) were female. The proportion of 
participants who had previously made a decision about antibiotic use varied by subgroup: 
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physicians, N=56/64 (87.5%); relatives, N=16/99 (16.2%); and professional guardians, 
N=17/67 (25.4%). The proportions of participants who had made a decision about artificial 
hydration use were: physicians, N=57/64 (89.1%); relatives, N=15/99 (15.2%); and 
professional guardians, N=9/67 (13.4%). 
Decisional Conflict  
Baseline decisional conflict scores were comparable between trial arms (Table 5). 
Relative to the control arm, participants in the intervention arm had significantly lower DCS-
D scores related to decisions about antibiotics (b=-8.35, 95% CI, -12.43, -4.28) and artificial 
hydration (b=-6.02, 95% CI, -9.84, -2.20) at the one-month follow-up compared to at 
baseline. When participant subgroups were analyzed separately, DCS-D scores were 
significantly lower in the intervention arm, with the exception being professional guardians 
making decisions about artificial hydration (Table 5).  
Knowledge 
Baseline knowledge scores were comparable between trial arms (Table 6). Relative 
to the control arm, participants in the intervention arm scored significantly higher on the 
knowledge scales related to the use of antibiotics (b=2.24, 95% CI, 1.79, 2.68) and artificial 
hydration (b=3.01, 95% CI, 2.53, 3.49) at the one-month follow-up compared to at baseline. 
Knowledge scores were significantly higher in the intervention arm for each participant 
subgroup for both treatment conditions (Table 6). 
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Table 5. The effects of Fact Box decision support tools on participants' decisional conflict about the use of 
antibiotics for pneumonia and artificial hydration in advanced dementia (N=232) 
Participants 
Baseline Decisional Conflictb 
Mean ± Standard Deviation	
1 Month Decisional 
Conflict Mean ± Standard 
Deviation Intervention Effectc 
Unstandardized beta 
(95% Confidence 
Interval) Intervention Control 
P 
Value 
Intervention, 
Review Fact 
Boxes Control 
All, No.d 114 118  114 118  
Decisional 
conflict about       
Antibiotic use 38.5 ± 18.0 39.0 ± 21.1 .84 28.7 ± 16.5 37.2 ± 20.3 -8.35 (-12.43, -4.28)*** 
Artificial 
hydration use 36.4 ± 17.9 36.9 ± 20.4 .86 30.1 ± 17.8 36.0 ± 19.0 -6.02 (-9.84, -2.20)** 
Physicians, No.d 30 34  30 34  
Decisional 
conflict about       
Antibiotic use 32.8 ± 12.4 29.3 ± 14.1 .30 26.0 ± 13.7 28.3 ± 12.5 -5.90 (-11.48, -0.32)* 
Artificial 
hydration use 30.4 ± 17.0 26.5 ± 15.1 .35 25.4 ± 13.2 27.0 ± 13.2 -6.41 (-12.11, -0.65)* 
Relatives, No.d 51 49  51 49  
Decisional 
conflict about       
Antibiotic use 33.5 ± 16.5 39.8 ± 24.5 .15 23.5 ± 15.9 35.9 ± 21.4 -8.02 (-14.81, -1.16)* 
Artificial 
hydration use 33.5 ± 15.3 37.1 ± 20.9 .36 23.5 ± 14.7 33.5 ± 17.6 -8.73 (-14.42, -3.02)** 
Professional 
Guardians, No.d 33 35  33 35  
Decisional 
conflict about       
Antibiotic use 51.2 ± 18.8 47.8 ± 17.9 .46 39.4 ± 15.2 48.1 ± 20.4 -10.96 (-19.34, -2.65)* 
Artificial 
hydration use 45.9 ± 18.8 47.3 ± 19.4 .78 44.6 ± 17.8 46.4 ± 21.1 -1.31 (-9.60, 7.02) 
aThe validated German version of the Decisional Conflict Scale (DCS-D), range 0-100, higher scores indicate 
greater conflict. 
bBaseline differences were analyzed using independent t-tests or chi-squared tests for continuous or 
categorical variables, respectively. 
cThe Fact Box effects were analyzed using linear mixed effects models, which accounted for repeated 
measurements among individuals. *P Value < 0.05; **P Value < 0.01; and ***P Value < 0.001. 
dMissing values are shown in Appendix B6. 
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Table 6. The effects of Fact Box decision support tools on participants' knowledge about the use of antibiotics 
for pneumonia and artificial hydration in advanced dementia and on preferences to forego these interventions 
(N=232) 
Participants  
Baselinea No. (%) or Mean ± 
Standard Deviation 
1 Month No. (%) or Mean ± 
Standard Deviation Intervention Effectsb 
Unstandardized beta 
(95% Confidence 
Interval) Intervention Control 
P 
Value 
Intervention, 
Review Fact 
Boxes Control 
All, No.c 114 118  114 118  
Knowledge aboutd       
Antibiotic use 3.0 ± 1.8 2.9 ± 1.7 .65 5.3 ± 1.7 3.0 ± 1.8 2.24 (1.79, 2.68)*** 
Artificial hydration 
use 2.7 ± 2.0 2.7 ± 1.8 .95 5.8 ± 1.2 2.8 ± 1.8 3.01 (2.53, 3.49)*** 
Preferences to foregoe       
Antibiotic use 49 (43.4) 52 (44.8) .93 78 (69.0) 60 (50.8) 2.29 (1.08, 4.84)*f 
Artificial hydration 
use 73 (64.0) 75 (64.1) >.99 82 (72.6) 84 (71.2) 1.07 (0.49, 2.36)
f 
Physicians, No.c 30 34  30 34  
Knowledge aboutd       
Antibiotic use 4.2 ± 1.5 4.6 ± 1.4 .33 6.4 ± 0.9 4.9 ± 1.5 1.90 (1.21, 2.59)*** 
Artificial hydration 
use 4.8 ± 1.1 4.4 ± 1.0 .13 6.0 ± 0.8 4.7 ± 1.2 0.94 (0.33, 1.54)** 
Preferences to foregoe       
Antibiotic use 14 (46.7) 18 (52.9) .80 22 (73.3) 21 (61.8) 2.19 (0.51, 9.33)f 
Artificial hydration 
use 26 (86.7) 25 (73.5) .32 27 (90.0) 27 (79.4) 1.00 (0.14, 7.01)
f 
Relatives, No.c 51 49  51 49  
Knowledge aboutd       
Antibiotic use 2.7 ± 1.9 2.3 ± 1.3 .18 5.1 ± 1.5 2.3 ± 1.1 2.41 (1.73, 3.09)*** 
Artificial hydration 
use 2.0 ± 1.8 2.0 ± 1.6 >.99 5.9 ± 1.1 1.9 ± 1.4 4.00 (3.30, 4.70)*** 
Preferences to foregoe       
Antibiotic use 31 (60.8) 25 (52.1) .50 42 (84.0) 29 (59.2) 2.54 (0.74, 8.76)f 
Artificial hydration 
use 34 (66.7) 30 (61.2) .72 39 (78.0) 34 (69.4) 1.23 (0.36, 4.18)
f 
Professional 
Guardians, No.c 33 35  33 35  
Knowledge aboutd       
Antibiotic use 2.4 ± 1.3 2.2 ± 1.5 .67 4.6 ± 1.9 2.1 ± 1.5 2.34 (1.38, 3.30)*** 
Artificial hydration 
use 2.1 ± 1.6 2.1 ± 1.7 .95 5.6 ± 1.5 2.2 ± 1.5 3.37 (2.43, 4.32)*** 
Preferences to foregoe       
Antibiotic use 4 (12.5) 9 (26.5) .26 14 (42.4) 10 (28.6) 4.64 (0.90, 23.95)f 
Artificial hydration 
use 13 (39.4) 20 (58.8) .18 16 (48.5) 23 (65.7) 1.08 (0.27, 4.29)
f 
aBaseline differences were analyzed using independent t-tests or chi-squared tests for continuous or 
categorical variables, respectively. 
bThe Fact Box effects were analyzed using linear mixed effects or logistic regression models for continuous or 
categorical variables, respectively. The mixed effects models accounted for repeated measurements among 
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individuals. *P Value < 0.05; **P Value < 0.01; and ***P Value < 0.001. 
cMissing values are shown in Appendix B7. 
dKnowledge was ascertained using 7-item true-false scales specific to the use of each treatment (scored, 
1=true, 0=false/don’t know; range 0-7, higher scores indicate greater knowledge). The scales and proportions 
of correct responses per item are shown in Appendices B3 and B4 in the supplementary data, available in Age 
and Ageing online. 
ePreferences to use antibiotics and artificial hydration were measured using single questions with the response 
options: ‘use’, ‘forego’, or ‘undecided’. 
fUnstandardized beta for categorical variables were transformed into odds ratios. 
 
Preferences to Forego Interventions  
Baseline decisions on antibiotic use were comparable between trial arms and 
distributed as follows (Table 6): N=80/229 (34.9%); forego, N=101/229 (44.1%); and 
undecided, N=48/229 (21.0%). Baseline decisions on artificial hydration use were also 
comparable and had the following distribution: use, N=46/231 (19.9%); forego, N=148/231 
(64.1%); and undecided, N=37/231 (16.0%).  
Relative to the control arm, participants who received the Fact Box in the intervention 
arm were significantly more likely to prefer to forego antibiotics (OR, 2.29, 95% CI, 1.08, 
4.84) at the one-month follow-up compared to at baseline. The intervention did not 
significantly impact preferences to forego artificial hydration, and treatment preferences did 
not differ when analyzed separately in each subgroup. 
Acceptability of Fact Boxes  
Among intervention participants, 86.8% (N=99/114) and 75.4% (N=86/114) found the 
Fact Boxes to be ‘helpful’ or ‘rather helpful’, respectively. Most participants rated the content 
as ‘very good’ or ‘good’ (antibiotics, N=79/112 (70.5%); artificial hydration, N=76/112 
(67.9%)). Similarly, most participants positively rated the layout (antibiotics, N=91/113 
(80.5%); artificial hydration, N=88/113 (77.9%)). While 64.3% (N=72/112) of participants 
rated the amount of information in both Fact Boxes as ‘exactly right’, 34.8% (N=39/112) and 
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33.9% (N=38/112) found the information to be ‘too little’ in the antibiotic and artificial 
hydration Fact Boxes, respectively. All but one physician (N=29/30, (96.7%)) were agreeable 
to using Fact Boxes in practice (agree, N=16/30 (53.3%); somewhat agree, N=13/30 
(43.3%)). 
4.4. Discussion 
In this RCT, participants who received Fact Box decision support tools in the 
intervention arm showed significantly less decisional conflict about the use of antibiotics for 
pneumonia and artificial hydration in advanced dementia at the one-month follow-up 
compared to at baseline and relative to participants in the control arm. Fact Box recipients 
also showed greater knowledge about the use of these treatments and were more likely to 
prefer to forego antibiotics. However, the intervention did not impact preferences to withhold 
artificial hydration. Most users rated the Fact Boxes positively on helpfulness, content, 
layout, and length, and 97% of physicians stated that they would use them as a 
communication tool.  
This RCT builds upon limited prior research examining the effects of decision support 
tools in advanced dementia (Einterz et al., 2014; Hanson et al., 2011; 2017; Mitchell et al., 
2001; Snyder et al., 2013; Volandes, Barry, Chang, & Paasche-Orlow, 2009a; Volandes, 
Paasche-Orlow, Barry, Gillick, Minaker, et al., 2009b). The findings corroborate the 
beneficial impact of these instruments on reducing decisional conflict (Hanson et al., 2011; 
Mitchell et al., 2001; Snyder et al., 2013; Volandes, Barry, Chang, & Paasche-Orlow, 2009a). 
Furthermore, the reduction on decisional conflict we observed with our brief tool was similar 
to that of a more intense 20-minute decision support tool (Hanson et al., 2011). Compared to 
video-based supports,(Einterz et al., 2014; Hanson et al., 2017; Volandes, Barry, Chang, & 
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Paasche-Orlow, 2009a; Volandes, Paasche-Orlow, Barry, Gillick, Minaker, et al., 2009b) 
Fact Boxes are brief, handy, inexpensive, and easier to incorporate into real-life care settings. 
Fact Boxes are unique in that they can be used by a variety of decision-makers, such 
as physicians, relatives of dementia patients, and professional guardians. This is evident by 
our findings that decisional conflict and knowledge improved in all of these different groups, 
compared to other tools designed for only one category of decision-makers (Einterz et al., 
2014; Hanson et al., 2011; Mitchell et al., 2001; Snyder et al., 2013; Volandes, Barry, Chang, 
& Paasche-Orlow, 2009a). All but one physician (N=29/30) were agreeable to using Fact 
Boxes in practice, which is consistent with a prior study demonstrating the appeal of brief 
decision support tools to physicians (Giguere et al., 2015). Our findings that Fact Boxes aided 
professional guardians is particularly notable because it was relatively unknown what type of 
decision support they would benefit from when making end-of-life choices for patients (A. B. 
Cohen et al., 2015). The finding that one Fact Box impacted preferences to forego antibiotics 
is also noteworthy, as it suggests comfort-focused care can be promoted by a less time 
intensive decision support tool than previously identified (Einterz et al., 2014; Hanson et al., 
2011; 2017; Volandes, Barry, Chang, & Paasche-Orlow, 2009a; Volandes, Paasche-Orlow, 
Barry, Gillick, Minaker, et al., 2009b). 
Several limitations merit discussion. First, our recruitment process resulted in lower 
participation rates than studies that recruited from medical institutions (Hanson et al., 2011; 
Mitchell et al., 2001). Therefore, our findings cannot be generalized to eligible non-
participants. Second, generalizability is also limited to the Swiss-German region of 
Switzerland and to hypothetical decisions. The effect of the intervention may vary in other 
regions and in real-world situations. Lastly, the statistical power may have been insufficient 
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to detect significant differences in subgroups (e.g., decisional conflict about artificial 
hydration use in professional guardians) and secondary outcomes (e.g., preferences to forego 
artificial hydration).  
In this RCT, Fact Box decision support tools reduced participants’ decisional conflict 
in hypothetical scenarios about the use of antibiotics for pneumonia and artificial hydration in 
advanced dementia. Both Fact Boxes increased participants’ knowledge about each treatment 
and the Fact Box on antibiotics led to an increase in preferences to withhold this intervention. 
Through improving the quality of decision-making for a variety of decision-makers, 
potentially promoting less aggressive care, and providing physicians with a useful 
communication tool, Fact Boxes may be a promising decision support tool for real-world 
settings. 
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5. Study 3: Perceptions about Controversial End-of-Life Practices 
 
Physician and Surrogate Agreement with Assisted Dying and 
Continuous Deep Sedation in Advanced Dementia in Switzerland3 
 
5.1. Introduction 
Dementia afflicts more than 50 million people worldwide and is one of the most 
common causes of death in Switzerland, and worldwide (Federal Statistical Office FSO, 
2017; World Health Organization, 2015a). In advanced dementia, patients have profound 
cognitive and functional deficits and experience clinical complications that may cause 
discomfort and a poor quality of life (Hendriks et al., 2014; Mitchell et al., 2009; van der 
Steen et al., 2016). 
Assisted dying is a controversial practice that has been used in certain contexts among 
patients with life-limiting disease (E. J. Emanuel et al., 2016). Assisted dying is when a 
physician either administers drugs that cause a person to die (i.e., euthanasia) or provides 
lethal drugs for self-administration (i.e., physician-assisted suicide) (Radbruch et al., 2016). 
To date, physician-assisted dying is legal in only a few states in the United States and a 
limited number of countries, including Switzerland (E. J. Emanuel et al., 2016; Li et al., 
2017). However, only the Netherlands, Belgium, and Luxembourg allow assisted dying for 
people with advanced dementia (Neil, 2016). This request must be made in an advanced 
directive by a patient with dementia when decision-making capacity is still intact. Only 
                                                
3 A similar version of this chapter is currently being prepared for publication (Loizeau, Cohen, Mitchell, Theill, 
Eicher, Martin, & Riese).  
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limited research exists on the perceptions of physicians and surrogates about the use of 
assisted dying in advanced dementia (Bolt et al., 2015; Kouwenhoven et al., 2015; Tomlinson 
et al., 2015; Tomlinson & Stott, 2014). 
Another controversial practice for terminally ill patients is continuous deep sedation 
until death (CDS). This is an intensive palliative practice that is used as a last resort to 
alleviate suffering (Miccinesi et al., 2006; Ziegler et al., 2018). Medications are administrated 
until death to lower the level of consciousness and relieve refractory symptoms of patients 
with a life expectancy of typically less than two weeks (Cherny et al., 2009). To date, CDS 
has predominantly been used among advanced cancer patients who experience extreme 
physical suffering in their final weeks of life (McCarthy et al., 2000; Miccinesi et al., 2006). 
CDS has rarely been used in advanced dementia, a condition predominantly characterized by 
cognitive impairments with some, but typically less, physical suffering than metastatic cancer 
(Anquinet et al., 2013; Hendriks et al., 2014; van der Steen et al., 2016). 
To better understand the perceptions of physicians and surrogates about the use of 
assisted dying and CDS in advanced dementia, we analyzed baseline data from a randomized 
controlled trial (RCT), the DEMentia FACT box (DEMFACT), conducted in the Swiss-
German region of Switzerland. The objectives of this report were to: 1) describe physician 
and surrogate agreements with the use of assisted dying and CDS in advanced dementia, and 
2) compare the agreements with the use of these practices in these two groups. 
5.2. Methods 
Data source 
Data were drawn from baseline assessments ascertained in the DEMFACT study 
conducted between June, 2016 and October, 2016 in the Swiss-German region of 
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Switzerland. DEMFACT was a RCT that evaluated FACT box decision-support tools for 
treatment decisions in advanced dementia among 64 physicians and 168 surrogates (relatives 
of dementia patients, N=100; professional guardians, N=68) who were randomized to either 
the intervention (N=114) or control arm (N=118) (Loizeau et al., n.d.). Intervention and 
control arm participants were mailed written questionnaires at baseline and one month later 
that asked questions about the use of treatments for advanced dementia patients based on 
hypothetical scenarios. At the one-month follow-up, intervention participants received the 
decision support tools, whereas control participants were given no additional information. 
The main DEMFACT study compared changes in pre-specified outcomes between the 
baseline and follow-up assessments in the intervention arm relative to the control arm. In this 
report, combined data from the baseline questionnaires in both arms (i.e., before receiving the 
decision support tools in the intervention arm) were analyzed to describe agreements with the 
use of continuous sedation and assisted dying in advanced dementia. Baseline questionnaires 
were completed between June 2, 2016 and July 31, 2016. The ethics commission of the 
canton of Zurich approved the study’s conduct (KEK-ZH-No. 2015-0626). All participants 
provided written informed consent. 
Population 
To understand the impact of the DEMFACT intervention on various decision-makers, 
participants included physicians and surrogates (relatives of dementia patients and 
professional guardians) who were potentially responsible for the care of advanced dementia 
patients. Physicians were identified from the mailing lists of the Swiss Association for 
Palliative Medicine, Care and Support, and the Swiss Geriatric Medicine Society. Surrogates 
were identified either through the Alzheimer Association of the canton of Zurich or from the 
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Swiss Association of Professional Guardians mailing list. The detailed recruitment procedure 
is described elsewhere (Loizeau et al., n.d.). Eligible participants were mailed a consent form, 
which they were asked to sign and return to the research team. 
Data Elements 
Data collection was procedurally identical across physician and surrogate participants. 
All variables in this report were collected at the DEMFACT baseline assessment using a 
written questionnaire sent and returned by mail (approximately 60 minutes to complete).  
The outcomes were participants’ agreement with the use of assisted dying and CDS in 
advanced dementia. Agreements with assisted dying were ascertained using the following 
question: ‘The current legislation prohibits physician-assisted suicide (assisted dying) for 
persons lacking the capacity to consent. This prevents persons with advanced dementia from 
accessing the services of assisted dying organizations. Independent of the current legal 
situation, would you personally support the use of assisted suicide (one form of physician-
hastened death) for persons with advanced dementia?’ Perceptions about the use of CDS 
were measured using the following question: ‘At the end of life, it is possible to use 
medications, administered until death, to relieve the symptoms of a person with advanced 
dementia and put them into a permanent, artificial sleep (continuous sedation). Would you 
personally support the use of continuous sedation for persons with advanced dementia?’ For 
both questions, participants were asked to select one of the following response options: 
‘completely agree’, ‘somewhat agree’, ‘somewhat disagree’, ‘completely disagree’, or ‘do not 
know’. 
Other participant data ascertained at baseline included: demographics (age, gender, 
nationality (Swiss, German, and other), religion (Protestant or Catholic, other religion, no 
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religion, and refused to answer), and educational level (≥ high school versus other)); and 
whether participants had previously made a decision about the use of antibiotics and/or 
artificial hydration for a person with advanced dementia. 
Analysis 
Analyses were performed using R Version 3.3.2 (Boston, MA). Means with standard 
deviations (SDs) and frequencies described continuous and categorical variables, 
respectively.  
Logistic regression was used to examine the association between decision-maker type 
(surrogate versus physician) and agreement with the following practices in advanced 
dementia (outcomes); 1. assisted dying and 2. CDS. For each practice, the outcome was 
dichotomized as ‘agree’ (i.e., ‘completely agree’ and ‘somewhat agree’) versus ‘disagree’ 
(i.e., ‘completely disagree’ and ‘somewhat disagree’), and excluded ‘do not know’ responses. 
Covariates considered a priori to be possibly associated with supporting the use of assisted 
dying or CDS,(Tomlinson & Stott, 2014) included: participant demographic characteristics 
(age (dichotomized at median), gender, and religion (dichotomized as no religion versus any, 
excluding ‘refused to answer’)); and prior decisions about the use of antibiotics and/or 
artificial hydration in advanced dementia (dichotomized as no prior major treatment decision 
versus any). Bivariable analyses examined the unadjusted associations between each 
covariate and the outcome. Variables associated with the outcome at P < 0.10 in the 
unadjusted analyses were entered into a multivariable model. The final adjusted model 
included those variables significantly associated with the outcome at P < 0.05. Adjusted odds 
ratios (ORs) with 95% Confidence Intervals (CIs) were computed.  
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5.3. Results 
Subject Characteristics  
Of the 3860 individuals approached for participation, 254 (6.6%) contacted the 
research team indicating their willingness to participate, and all were eligible for enrollment. 
Prior to study completion, 15 (5.9%) participants stopped responding to e-mails and/or phone 
calls (physicians, N=9/74 (12.2%); surrogates, N=6/180 (3.3%)) and 7 (2.8%) participants 
withdrew (physicians, N=1/74 (1.4%); surrogates, N=6/180 (3.3%)). The final sample size 
included the remaining 64 physicians and 168 surrogates. 
Table 7. Physician and Surrogate Characteristics (N=232) 
Characteristics 
Physicians 
(N=64), 
No. (%) 
Surrogates 
(N=168), No. 
(%) 
Age, mean ± standard deviationa 50.6 ± 9.9 57.4 ± 14.6 
Age > 55 (median) 21 (32.8) 91 (54.5) 
Femalea 30 (46.9) 115 (68.9) 
Nationality   
Swiss 44 (72.1) 157 (94.6) 
German 13 (21.3) 7 (4.2) 
Other  4 (6.6) 2 (1.2) 
Religiona   
Protestant or catholic 44 (68.8) 108 (65.5) 
Other 9 (14.1) 11 (6.7) 
No religion 10 (15.6) 38 (23.0) 
Refused to answer 1 (1.6) 8 (4.8) 
Education   
≥ high school 64 (100) 161 (97.0) 
Any prior major treatment decision in 
dementiaa,b 58 (90.6) 42 (25.3) 
aThe total number of missing values by characteristic was: age, N=1; 
female, N=1; nationality, N=5; education, N=2; religion, N=3; and any 
prior major treatment decision, N=2. 
bDecision-makers reported whether they had or had not previously 
made any major decision about the use of antibiotics and/or artificial 
hydration for a person with advanced dementia. 
 
The baseline characteristics of the physicians and surrogates are shown in Table 7. 
The physicians’ mean (SD) age was 50.6 (9.9) years, 46.9% (N=30/64) were women, and 
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72.1% (N=44/61) were Swiss. The surrogates’ mean (SD) age was 57.4 (14.6) years, 68.9% 
(N=115/167) were women, and 94.6% (N=157/166) were Swiss. A total of 68.8% (N=44/64) 
of physicians and 65.5% (N=108/165) of surrogates reported being either Protestant or 
Catholic. A total of 90.6% (N=58/64) of physicians had previously made a major treatment 
decision for a person with advanced dementia, whereas only 25.3% (N=42/166) surrogates 
had ever made such a decision. 
Agreement with Assisted Dying 
The distribution of physician responses about the use of assisted dying in advanced 
dementia was as follows: completely agree, 4.7% (N=3/64); somewhat agree, 15.6% 
(N=10/64); somewhat disagree, 26.6% (N=17/64); completely disagree, 50.0% (N=32/64); 
and do not know, 3.1% (N=2/64). The distribution among surrogates was: completely agree, 
20.2% (N=34/168); somewhat agree, 26.8% (N=45/168); somewhat disagree, 23.2% 
(N=39/168); completely disagree, 22.6% (N=38/168); and do not know, 7.1% (N=12/168).  
In the unadjusted analyses, participant variables associated with agreement with 
assisted dying at a P < 0.10 were: age > 55 years; any prior major treatment decision in 
dementia; and being a surrogate (versus a physician) (Table 8). After multivariable 
adjustment, only being a surrogate (versus a physician) remained significantly associated 
with a higher likelihood of agreeing with the use of assisted dying (adjusted OR, 3.87; 95% 
CI, 1.94, 7.69). 
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Table 8. Association between decision-maker type and agreement with the use of assisted dying in advanced 
dementiaa 
  
Total No. (%) 
of Decision-
Makers with 
Characteristic 
(N=218) 
No. (%) of Decision-Makers 
Agreeing with Assisted 
Dying (N=92) 
Odds Ratiob for Agreement with 
Assisted Dying (95% Confidence 
Interval) 
Characteristic 
With 
Characteristic 
Present 
With 
Characteristic 
Absent Unadjusted Adjusted 
Surrogates (versus 
physicians)  156 (71.6) 79 (36.2) 13 (6.0) 3.87 (1.94, 7.69)
e 3.87 (1.94, 7.69) 
Covariates      
Age > 55 (median)c 106 (48.8) 54 (24.9) 38 (17.5) 1.99 (1.15, 3.45)e  
Femalec 133 (61.3) 62 (28.6) 30 (13.8) 1.57 (0.90, 2.76)  
No religious affiliation 
(versus any)c 45 (21.4) 24 (11.4) 67 (31.9) 1.67 (0.86, 3.24)  
Any prior major 
treatment decision in 
dementiad 
97 (44.9) 29 (13.4) 61 (28.2) 0.41 (0.23, 0.71)e  
aDecision-makers were 42.2% (N=92/218) agreeing with the use of assisted dying in advanced dementia. 
bLogistic regression was used in all analyses, and unadjusted and adjusted odds ratio were computed. 
cThe total number of missing values was: age, N=1; female, N=1; no religion, N=8 (missing values, N=3; 
refused, N=5); and any prior major treatment decision, N=2. 
dDecision-makers reported whether they had or had not previously made any major decision about the use of 
antibiotics and/or artificial hydration for a person with advanced dementia. 
eVariables that were significant at P < 0.10 in bivariable analyses and entered into the multivariable model.  
 
Agreement with Continuous Deep Sedation  
The distribution of physician responses about the use of CDS in advanced dementia 
was as follows: completely agree, 20.3% (N=13/64); somewhat agree, 31.3% (N=20/64); 
somewhat disagree, 31.3% (N=20/64); completely disagree, 6.3% (N=4/64); and do not 
know, 10.9% (N=7/64). The distribution among surrogates was: completely agree, 12.6% 
(N=21/167); somewhat agree, 29.3% (N=49/167); somewhat disagree, 28.7% (N=48/167); 
completely disagree, 18.6% (N=31/167); and do not know, 10.8% (N=18). 
The only covariate associated with a greater likelihood of supporting the use of CDS 
at a P ≤ 0.10 was no religion (versus any) (Table 9). After adjusting for religion, being a 
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surrogate (versus a physician) was not significantly associated with agreement with the use of 
CDS (AOR, 0.69; 95% CI, 0.36, 1.29). 
Table 9. Association between decision-maker type and agreement with the use of continuous deep sedation in 
advanced dementiaa 
  
Total No. (%) 
of Decision-
Makers with 
Characteristic 
(N=206) 
No. (%) of Decision-Makers 
Agreeing with Continuous 
Deep Sedation (N=103) 
Odds Ratiob for Agreement with 
Continuous Deep Sedation (95% 
Confidence Interval) 
Characteristic 
With 
Characteristic 
Present 
With 
Characteristic 
Absent Unadjusted Adjusted 
Surrogates (versus 
physicians)  149 (72.3) 70 (34.0) 33 (16.0) 0.64 (0.35, 1.19) 0.69 (0.36, 1.29)
f 
Covariates      
Age > 55 (median)c 101 (49.3) 55 (26.8) 48 (23.4) 1.39 (0.81, 2.42)  
Femalec 128 (62.4) 64 (31.2) 39 (19.0) 0.97 (0.55, 1.71)  
No religion (versus 
any)c 41 (20.9) 27 (13.8) 74 (37.8) 2.11 (1.03, 4.33)
e 2.19 (1.06, 4.51) 
Any prior major 
treatment decision in 
dementiad 
88 (43.1) 47 (23.0) 55 (27.0) 1.27 (0.73, 2.22)  
aDecision-makers were 50.0% (N=103/206) agreeing with the use of continuous deep sedation in advanced 
dementia. 
bLogistic regression was used in all analyses, and unadjusted and adjusted odds ratio were computed. 
cThe total number of missing values was: age, N=1; female, N=1; no religion, N=10 (missing values, N=2; 
refused, N=8); and any prior major treatment decision, N=2. 
dDecision-makers reported whether they had or had not previously made any major decision about the use of 
antibiotics and/or artificial hydration for a person with advanced dementia. 
eThe only variable that was significant at P < 0.10 in bivariable analyses and entered into the multivariable 
model.  
fAfter adjusting for religion, the association between being a physician and supporting the use of continuous 
deep sedation until death remained not significant. 
 
5.4. Discussion 
In this report, a minority of physicians (20%) and about half of surrogates (47%) 
supported the use of assisted dying for patients with advanced dementia. Surrogates were 
significantly more likely to agree with the use of this practice than physicians. About half of 
physicians (52%) and a slightly lower proportion of surrogates (42%) agreed with the use of 
CDS for these patients, which was not a significant difference between groups. 
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This study confirms and furthers limited existing research on the perceptions of 
physicians and surrogates about assisted dying in advanced dementia (Bolt et al., 2015; 
Kouwenhoven et al., 2015; Tomlinson et al., 2015; Tomlinson & Stott, 2014). The use of 
assisted dying has increased in countries where it is legal (the Netherlands and Belgium) over 
the last decade, but much less frequently for patients with dementia compared to those with 
terminal illnesses that do not impact decision-making abilities (Dierickx et al., 2017; E. J. 
Emanuel et al., 2016; Neil, 2016). Prior research has shown that most physicians are opposed 
to the use of this practice in dementia (Bolt et al., 2015; Kouwenhoven et al., 2015; 
Tomlinson & Stott, 2014). Regardless of the presence of an advance directive, physicians are 
reluctant to perform physician-assisted suicide for patients lacking decision-making capacity 
(Kouwenhoven et al., 2015). A Dutch study of 1456 physicians found that physicians were 
more willing to perform assisted dying for cancer patients with intact cognition (85%) than 
for advanced dementia patients who requested euthanasia in an advance directive prepared 
when they were still capable of making medical decisions (33%) (Bolt et al., 2015). One chief 
concern is that preferences change over time,(E. J. Emanuel et al., 2000) and that patients 
who imagine a future state with advanced dementia as one not worth living, once in that state, 
they may appear to still retain a desire to live. Although surrogates may share this concern, 
their more favorable view of the use of assisted dying may be driven by a relatively greater 
aversion to their loved one experiencing the poor quality of life, suffering, and indignities of 
advanced dementia (Tomlinson et al., 2015; Tomlinson & Stott, 2014). The greater likelihood 
of surrogates agreeing to assistance in dying is that their participation, unlike physicians, is 
not required to complete the act. 
Our findings build on the very limited data on the use of CDS in advanced 
dementia,(Anquinet et al., 2013; Hendriks et al., 2014) and reveal that there is no consensus 
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among either physicians or surrogates about the appropriateness of using CDS in this 
population. This finding corroborates qualitative research showing that both groups of key 
decision-makers have mixed feelings about the use of this practice among terminally ill 
patients (Bruinsma, Rietjens, Seymour, Anquinet, & van der Heide, 2012; Ziegler, Merker, 
Schmid, & Puhan, 2017). To date, CDS has predominantly been used and studied in 
advanced cancer, a condition where decision-making capacity remains intact and the dying 
process is most commonly accompanied by intractable physical pain and suffering 
(McCarthy et al., 2000; Miccinesi et al., 2006). In contrast to these patients, advanced 
dementia patients cannot participate in decision-making or report the source of their 
discomfort due to their serious cognitive impairments (van der Steen et al., 2016). Although 
pain is generally under-detected and under-treated in advanced dementia, physical suffering 
is not the primary symptom of this condition, unlike metastatic diseases (McCarthy et al., 
2000; Morrison & Siu, 2000a). It also may be challenging for physicians to assess the 
intensity of a patient’s suffering, making it difficult to justify the use of CDS in advanced 
dementia. Furthermore, pain and agitation in advanced dementia are often caused by other 
medical complications, such as infections, and may be effectively controlled with standard 
palliative medications (Hendriks et al., 2014; Mitchell et al., 2009). 
This study has several limitations that merit discussion. First, our participation rate 
was low and thus our findings cannot be generalized to eligible non-participants. Second, 
generalizability is also limited to the Swiss-German region of Switzerland and to hypothetical 
situations. The perceptions about end-of-life practices may vary in other regions of 
Switzerland and in real-life situations. Third, the questions may not have been detailed 
enough to detect nuances in participants’ perceptions (Magelssen, Supphellen, Nortvedt, & 
Materstvedt, 2016). It is likely that participants’ opinions would have been different if they 
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were given more information, such as a statement indicating the patient made a written 
request for assisted dying before losing decision-making capacity. Lastly, the statistical 
power may have been insufficient to detect significant differences in secondary outcomes, 
notably differences in perceptions about CDS.  
This study expands upon the limited existing literature on the perceptions of 
physicians and surrogates about the use of assisted dying and CDS in patients with advanced 
dementia. Physicians were more opposed to the use of assisted dying than surrogates, and 
about half of participants in both groups perceived CDS as an appropriate option in advanced 
dementia. In general, there is a clear need to improve end-of-life care in this patient 
population. However, due to the pratical, ethical, and legal issues associated with performing 
assisted dying and CDS for patients who lack decision-making capacity, it remains unclear 
whether these practices would help accomplish this goal. 
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6. General Discussion 
This thesis aimed to advance our understanding of and improve medical decision-
making in advanced dementia among various decision-makers by examining associations 
between decision-making supports and health outcomes in both decision-makers and patients. 
Findings from studies 1, 2, and 3 inform decision-making and are illustrated in Figure 3 using 
an extension of the Quality of Care model by Donabedian (Donabedian, 1988; Teno et al., 
1997). 
 
Figure 3. Contribution of studies 1-3 illustrated using the Quality of Care Model 
All studies corroborated and went beyond the extant research landscape on 
burdensome contexts of decision-making (Engel, Kiely, & Mitchell, 2006; Givens et al., 
2009; Pautex et al., 2013; You et al., 2015). Studies 1 and 2 identified the positive impact of 
proxy counseling and decision-supports (processes) on outcomes in both decision-makers 
(studies 1 and 2) and patients (study 1 only). Study 3 provides novel insights into decision-
makers’ mixed perceptions about controversial end-of-life practices.  
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6.1. Summary of Findings 
Study 1 determined the accuracy of proxies’ prognostic estimates for nursing home 
residents with advanced dementia, identified factors associated with those estimates, and 
examined the association between their estimates and use of burdensome interventions. Data 
were combined from two studies that prospectively followed 764 residents with advanced 
dementia and their proxies in Boston area nursing homes for 12 months: 1. The Study of 
Pathogen Resistance and Exposure to Antimicrobials in Dementia, conducted from 
September 2009 to November 2012 (362 resident/proxy dyads; 35 facilities); and 2. The 
Educational Video to Improve Nursing Home Care in End-stage Dementia conducted from 
March 2013 to July 2017 (402 resident/proxy dyads; 62 facilities). During quarterly 
telephone interviews, proxies stated whether they believed the resident would live less than 1 
month, 1 to 6 months, 7 to 12 months, or more than 12 months. Prognostic estimates were 
compared with resident survival. Resident and proxy characteristics associated with proxy 
prognostic estimates were determined. Furthermore associations between prognostic 
estimates and whether residents experienced any of the following were also determined: 
hospital transfers, parenteral therapy, tube feeding, venipunctures, and bladder 
catheterizations. Findings showed that proxies of nursing home residents with advanced 
dementia predicted how long the resident would live with moderate accuracy. Having been 
asked about their opinion about the goals of care was the factor most strongly associated with 
the proxies’ perception that the resident had less than 6 months to live. Residents were 
significantly less likely to experience burdensome interventions when their proxies perceived 
they would die within 6 months. These findings suggest that proxies are reasonably good at 
estimating when residents with advanced dementia will die and their prognostic perceptions 
may influence the type of care the resident receives. 
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Study 2 tested the impact of Fact Box decision support tools on decisional conflict, 
knowledge, and preferences about the use of antibiotics and artificial hydration in advanced 
dementia. The DEMentia FACT box (DEMFACT) was a randomized controlled trial that 
followed 232 participants (intervention, 114; control, 118) (64 physicians, 100 relatives of 
dementia patients, 68 professional guardians) in the Swiss-German region of Switzerland. 
Participants received written questionnaires at baseline and one month later in which they 
were asked questions about hypothetical treatment scenarios. Intervention participants 
received Fact Box decision support tools (two-page, pocket-sized brochures) on antibiotics 
for pneumonia and artificial hydration in advanced dementia at the one-month follow-up. The 
primary outcome was change in decisional conflict (DCS-D; range 0<100) about treatment 
decisions. Secondary outcomes included knowledge about treatments (range 0<7) and 
preferences to forego treatments. Findings showed that participants who received Fact Box 
decision support tools in the intervention arm showed significantly less decisional conflict 
about the use of antibiotics for pneumonia and artificial hydration in advanced dementia at 
the one-month follow-up compared to at baseline and relative to participants in the control 
arm. Fact Box recipients also showed greater knowledge about the use of these treatments 
and were more likely to prefer to forego antibiotics. However, the intervention did not impact 
preferences to withhold artificial hydration. Most users rated the Fact Boxes positively on 
helpfulness, content, layout, and length, and 97% of physicians stated that they would use 
them as a communication tool. These findings suggest that Fact Box decision support tools 
reduced decisional conflict, increased knowledge, and promoted preferences to forego 
antibiotics in advanced dementia among various decision-makers. 
Study 3 described and compared physician and proxy perceptions about the use of 
assisted dying and continuous deep sedation until death in advanced dementia. Sixty-four 
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Physicians and 168 proxies of persons with advanced dementia were recruited as part of the 
aforementioned DEMFACT study. At baseline, all participants were asked about the extent to 
which they would agree with the use of assisted dying and continuous deep sedation in 
advanced dementia patients using the following response options: completely agree, 
somewhat agree, somewhat disagree, completely disagree, or do not know. Multivariable 
logistic regression models compared the likelihood of agreement with these practices 
between proxies and physicians. Findings showed that a total of 20% of physicians and 47% 
of proxies agreed with assisted dying in advanced dementia. Proxies were significantly more 
likely to agree with this practice compared to physicians. Regarding to continuous deep 
sedation, 52% of physicians and 42% of proxies agreed with this practice, which did not 
differ significantly between groups. Therefore, these findings suggest that proxies were more 
likely to consider assisted dying in advanced dementia than physicians, and about half of 
participants in both groups reported continuous deep sedation to be an appropriate option for 
this population. 
6.2. Goals of Care Discussions as a Resource for Decision-Making 
Goals of care discussions, or proxy counseling in general, can positively influence 
end-of-life care (Givens et al., 2018; Hanson et al., 2017; Mitchell et al., 2009; 2017; van der 
Steen et al., 2013). Of the 2526 proxy interviews (cohort of 764 proxies of patients with 
advanced dementia) in study 1, proxies reported having had a goals of care discussion in only 
45% of interviews. This finding is in line with prior research showing that although these 
conversations can promote better care decisions, they are not always conducted in long-term 
care settings (Givens et al., 2009; 2018; Hanson et al., 2017). 
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Goals of care discussions are, per definition, optimal to discuss the patient’s goals of 
care. In study 1, proxies who had been asked by a physician about their opinion regarding the 
goal of care were more likely to perceive that the resident had less than 6 months to live. This 
perception was in turn associated with a lower likelihood that the resident experienced 
burdensome interventions. Although we do not know the specific content of the goals of care 
discussions, these discussions seem to play a crucial role in making proxies understand the 
terminal condition of advanced dementia, and thus in promoting comfort care instead of 
intensive care. Because most proxies are unaware of the poor prognosis in advanced 
dementia, they are very likely to make biased treatment decisions (Mitchell, Kiely, & Hamel, 
2004a; van der Steen et al., 2013). For example, if the proxy thinks that the patient will live 
longer than 12 months, the proxy may be more inclined to choose curative medications such 
as antibiotics. A more accurate perception about the poor prognosis in advanced dementia is 
therefore crucial for delivering goal-directed care. In this regard, our findings confirm that 
proxy perception of prognosis influence end-of-life care and expand on this notion by 
suggesting that goals of care discussions could play a role in this relationship. 
Goals of care discussions can help promote high-quality decision-making and goal-
directed care. But what exactly are the necessary attributes of a goals of care discussion for it 
to improve decision-making? According to the judgment and decision-making literature, 
available choice options are weighed by the decision-maker in order to subsequently select 
the option with the highest expected value (Rangel et al., 2008). In the context of treatment 
decisions on behalf of others, a decision-maker clearly needs to know all choice options 
before he can objectively maximize expected value. To subsequently and accurately represent 
the expected value of a given choice option in their value function, decision-makers need to 
incorporate information about the patient’s health as precisely as possible. Based on our study 
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and the existing literature, it is important for decision-makers to understand the following 
aspects of advanced dementia in order to make informed decisions: 1. terminal condition of 
dementia; 2. expected re-occurrence of complications; 3. benefit-to-harm ratio about 
treatment administration; 4. benefit-to-harm ratio about treatment effects; and 5. alternative to 
treatments. With this information in mind, proxies can coordinate with physicians to weigh 
goals of care options such as to prolonging life, maintaining functions or maximizing comfort 
in accordance with the patient’s preferences, if available (Mitchell et al., 2017; van der Steen 
et al., 2014). Going through those decision-making steps during a goals of care discussion 
can result in improved outcomes for both the decision-maker and the patient.  
Based on the WHO’s definition of Healthy Ageing as the process of developing and 
maintaining the functional ability that enables well-being in older age (page 28), one might 
be inclined to deduce that well-being is defined by health in a classical and strict sense 
(World Health Organization, 2015b). While this deduction may be correct in certain 
situations, in the case of critical and terminal illnesses where alleviating pain completely is no 
longer an option, the concept of well-being may be accurately thought of as the individuals’ 
ability to be and to do what they have reason to value (p. 28; World Health Organization, 
2015b). In those cases, well-being can thus be interpreted to result from decisions that are 
made in accordance with end-of-life preferences. In advanced dementia, however, patients 
lack decision-making capacity and their well-being completely depends on the decision-
maker’s ability to make decisions in line with their preferences. Because goals of care 
discussions can promote this process, they are a resource for high-quality decision-making 
and a means by which decision-makers and patients can experience well-being and in turn 
healthy ageing.  
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6.3. Decision Support Tools as a Resource for Decision-Making 
Decision support tools in advanced dementia can foster communication between 
decision-makers and result in better outcomes for both the decision-maker and patient 
(Einterz et al., 2014; Hanson et al., 2017; Volandes, Barry, Chang, & Paasche-Orlow, 2009a; 
Volandes, Paasche-Orlow, Barry, Gillick, Minaker, et al., 2009b). Although these tools have 
been found to be effective, most are videos tailored to only a single group of decision-maker. 
 Fact Boxes on the use of antibiotics and artificial hydration in advanced dementia are 
brief, handy, inexpensive, easier to incorporate into real-life care settings and tailored to 
various decision-makers. In study 2, Fact Box decision support tools reduced decisional 
conflict in hypothetical scenarios, increased knowledge, and promoted preferences to forego 
antibiotics in advanced dementia among various decision-makers. These findings suggest that 
simple Fact Boxes may be as effective as other more intensive tools in supporting decision-
making, and this not only in one single group of decision-makers but in various decision-
makers (Einterz et al., 2014; Hanson et al., 2017; Volandes, Barry, Chang, & Paasche-Orlow, 
2009a; Volandes, Paasche-Orlow, Barry, Gillick, Minaker, et al., 2009b). The fact that all 
decision-makers have increased their knowledge after reviewing the Fact Box suggests that 
all understood the provided information the same way. A prior study has shown that even 
after proxy counseling by physicians, both parties had different perceptions about the content 
of their conversations (D. B. White et al., 2016a). In the specific case of decision-making on 
behalf of someone else, it is particularly important that all involved decision-makers are on 
the same page. By providing similar, easily understandable, standardized information to 
various decision-makers, Fact Boxes could have the potential to reduced communication bias 
between these decision-makers.  
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This thesis investigated decision-making not only in relatives as most commonly in 
advanced dementia research but also in physicians. Study 2 found that Fact Boxes increased 
the knowledge of physicians about the use of antibiotics and increased preferences to forego 
antibiotics. The misuse of antibiotics by physicians among patients with advanced dementia 
is extensive and antimicrobial overuse causes the development of MDROs, a public health 
threat and worldwide concern (Ho et al., 2010; Mitchell et al., 2014; World Health 
Organization, 2014b). In this regard, by promoting a better physician understanding about the 
use of antibiotics in advanced dementia, simple Fact Boxes could potentially reduce the 
misuse of antibiotics and contribute to measures taken against the development of MDROs in 
frail patients.  
This thesis also spotlights the population of professional guardians. With an ageing 
global demographic, more patients with advanced dementia will have no family members 
available to make medical decisions on their behalf and thus decision-making by professional 
guardians will become even more likely (A. B. Cohen et al., 2015). Findings from study 2 
revealed the high decisional conflict of professional guardians about treatment decisions in 
advanced dementia and lack of knowledge, suggesting that this population would benefit 
from increased support. To date, most research on advanced dementia does not differentiate 
their outcomes from the ones of family decision-makers. Research should further explore 
their decision-making and subjective experience when they have neither physicians’ medical 
expertise nor relatives’ insights about patients’ history to draw from. 
In addition to addressing the needs of various decision-makers, this thesis sought to 
develop decision-support tools that could be easily implemented in busy and complex 
medical settings. Compared to other video decision support tools,(Einterz et al., 2014; 
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Hanson et al., 2017; Volandes, Barry, Chang, & Paasche-Orlow, 2009a; Volandes, Paasche-
Orlow, Barry, Gillick, Minaker, et al., 2009b) Fact Boxes are brief and handy; a format that 
could be more easily implemented and suitable to be used in direct communication. A prior 
randomized clinical trial in North-Carolina among 302 residents with advanced dementia and 
their family decision-makers has found that a goals of care video decision aid followed by a 
structured discussion improved end-of-life communication and enhance palliative care plans 
(Hanson et al., 2017). The video format in this trial did not allow using the decision support 
as direct communication tool. However, it seems that the most difficult challenge and barrier 
for decision-making is finding adequate language to transfer medical knowledge and discuss 
end-of-life preferences (Givens et al., 2009; 2012; Pautex et al., 2013; You et al., 2015). In 
contrast to the study by Hanson et al. (2017) where the video is first watched and then use as 
basis for discussion, Fact Box could be used in direct communication and their easily 
understandable language could help physicians, and potentially proxy decision-makers, 
finding adequate language. Consistent with a prior study demonstrating the appeal of brief 
decision support tools to physicians,(Giguere et al., 2015) in study 2 all but one physician (29 
of 30) stated they would use Fact Boxes as communication tool in practice.  
Research has examined the impact of decision-support tools on communication 
between providers and families at various time points in the medical settings (Einterz et al., 
2014; Hanson et al., 2017). Although this outcome measure is fundamental to assess quality, 
it may not be the only relevant outcome to capture the aspect dynamic of decision-making. 
The process of decision-making goes beyond the medical setting and really interferes in the 
life of decision-makers. Research has shown that family decision-makers report having 
difficulties coping with decision-making, in particular due to discordant opinions of other 
family members about the ‘right’ decision (Givens et al., 2012; Vig et al., 2007). To date, the 
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effects of decision support tools on the decision-maker’s own dynamic reflections and in 
relationship to other family members or friends has not been studied in advanced dementia. A 
study on dyadic coping among couples affected by cancer used audio recorders over one 
weekend to capture spontaneous conversations and found that cancer was a topic of 
approximately 5% of the couples’ conversations and the spouses’ engaged reflections 
predicted better patient adjustment (Robbins, López, Weihs, & Mehl, 2014). These findings 
suggest that the topic of chronic disease is part of everyday life conversation among affected 
families and structured decision aid could presumably enrich these conversations.  
Through improving decisional outcomes of a variety of decision-makers, potentially 
promoting less aggressive care, and providing physicians with a useful communication tool, 
Fact Boxes can promote high-quality decision-making and thus healthy ageing in both 
decision-makers and patients. Fact Boxes may be used as an information and communication 
support for goals of care discussions.  
6.4. Controversial End-of-Life Practices and Decision-Making 
When discussing medical decision-making in advanced dementia a topic certainly 
worth addressing pertains to decisions about more controversial end-of-life practices such as 
assisted dying and continuous deep sedation until death.  
Individuals age healthy when they can do what they have reason to value (p. 28; 
World Health Organization, 2015b). The ability to decide about one’s time of death is a 
source of control and freedom. Assisted dying is thus not just a matter of personal choice but 
also a potential opportunity for well-being. The fear of an impoverished existence and loss of 
control over life and death that may result from neurodegenerative diseases such as dementia 
explain increasing interest for assisted dying among the general population (Kouwenhoven et 
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al., 2012). It seems to be in some contrast, then, that 77% of physicians 46% of proxies would 
somewhat disagree or completely disagree with the use of assisted dying if they were 
responsible for a patient with advanced dementia. These findings corroborate prior research 
showing a divergence between personal decisions and those that are made on someone else’s 
behalf (Bolt et al., 2015; Kouwenhoven et al., 2015; Tomlinson & Stott, 2014). 
Although most proxies may support the idea that patients with advanced dementia 
have the right to die, they also report the challenging complexity of assisted dying among 
these patients (Tomlinson et al., 2015). Decision-makers may already face other decisions 
that imply having accepted the patient’s imminent death, such as deciding to forego life-
sustaining measures in order to meet the goals of care. In this sense, continuous deep sedation 
until death may be situated more towards the extreme end of the choice continuum. Although 
this practice does not hasten death, it does put the patient in an artificial sleep, allowing 
family members to prepare themselves for the patient’s death. Compared to assisted dying, a 
higher proportion of physicians (52%) agreed with sedation. While assisted dying is 
relatively more brutal and requires physicians to complete the final act, sedation is more in 
line with an understanding of death as a natural end-point. Sedation medications solely 
accompany the dying process without interfering with the natural time point of death in any 
drastic way.  
Advanced directives are substantial as they provide individuals a way to compensate 
for impaired decisional capacities and thus the opportunity to still do what they have reason 
to value (World Health Organization, 2015b). Because advanced directives inform about the 
patient’s preferences, they also provide significant help and relief for decision-makers when 
making care decisions on behalf of the patient. In the specific case of advanced euthanasia 
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directives, however, one chief concern is that preferences change over time,(E. J. Emanuel et 
al., 2000) and that patients who imagine a future with advanced dementia as one not worth 
living may still retain a desire to live once they are actually in that state. Given this 
uncertainty, physicians are often reluctant to take responsibility for a final act that might 
additionally go against their own values, even in the face of a request in an advanced 
euthanasia directive that was prepared when the patient’s decision-making capacity was still 
intact (Kouwenhoven et al., 2015). This reveals the delicate challenges of end-of-life 
decision-making on behalf of someone else: the degree to which decisions can be made in 
accordance with the patient’s preferences is informed by the extent to which they respect 
values of both the patient and decision-maker.  
Legalizing assisted dying for patients with advanced dementia does not necessarily 
make it permissible from the decision-maker’s perspective. Despite progress in palliative 
medicine, there are cases in which there are no alternative choices available that stabilize 
functional ability of the patient with advanced dementia, and choosing death may be the only 
way to respect the patient’s preferences and enable well-being. Notably, what may stabilize 
the functional ability of the decision-maker may not necessarily stabilize the functional 
ability of the patient, and vice versa. Given that control over the time point of death is a 
source of freedom and subsequently well-being and healthy ageing for both parties, adequate 
information throughout all stages could help synchronize preferences and thus optimize 
overall outcomes. 
6.5. Limitations 
This thesis has several limitations that merit discussion. First, the studies were limited 
to cohorts of participants living in Massachusetts (United States) and the Swiss-German 
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region of Switzerland. Findings thus may not generalize to other regions. Second, the 
recruitment process of the DEMFACT study (studies 2 and 3) relied on various organizations 
such as the Alzheimer Association Zurich, which resulted in lower participation rates (7%) 
compared to the combined cohorts of study 1 (the SPREAD study, 38%; the EVINCE study, 
37%) that recruited from medical institutions (Mitchell et al., 2013; 2014; 2017). Recruitment 
via medical institutions using multiple recruitment waves should be preferred over one-time 
recruitment via private organizations. Moreover, participation rates in the DEMFACT study 
were more than twice as high in physicians (13%) compared to relatives (5%) and 
professional guardians (6%). This difference may be explained by the specific medical topic 
as it may have been aversive to proxies without medical expertise who may not have been 
currently concerned with the topic under study. In this regard, too, recruiting via medical 
institutions may enable better targeting of the study population while also providing a form of 
middleman, which helps identify and ensure participation of eligible participants. Based on 
these considerations, our findings cannot be generalized to eligible non-participants. Third, 
the questions that were used to assessed proxy predictions of prognosis (study 1) and 
physicians and proxies perceptions about controversial end-of-life practices (study 3) may not 
have been detailed enough to capture nuances in respondents’ attitudes (Magelssen et al., 
2016; Perez-Cruz et al., 2014; N. White et al., 2017). In study 3, for example, participants 
were asked to ignore the fact that assisted dying in advanced dementia is illegal in 
Switzerland. An additional question without this caveat would have served to rule out that 
responses are otherwise anchored on the extant legal framework. However, studies from 
countries where assisted dying in advanced dementia is permitted found similar proportions 
in decision-maker’s perceptions (Bolt et al., 2015; Rurup et al., 2006). Fourth, the findings 
presented in this thesis do not speak to the exact factors which may have driven participants’ 
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perception of prognosis (study 1), changes in treatment decisions (study 2), and perceptions 
about controversial end-of-life practices (study 3). It is likely that some, potentially 
qualitative, elements not captured in the dataset may have impacted response outcomes. Fifth, 
despite the important finding that goals of care discussions could play a role in the 
relationship between proxy perception of prognosis and end-of-life care, the data does not 
license inferences about the nature of this relationship in terms of the exact attributes of a 
beneficial goals of care discussion. For instance, we cannot determine the relative impact of 
content, length, or physicians’ communication skills on the relevant outcomes in question. 
Lastly, statistical power may have been insufficient to detect significant differences in 
findings that were based on secondary outcomes (e.g., study 3), and future replications should 
serve to further rule out false positives.  
6.6. Research and Clinical Implications 
The three studies presented in this thesis have significant implications for research in 
advanced dementia and palliative care, as well as for clinical practice in terms of care 
management of patients with advanced dementia. On an even larger scale, implications may 
extend to the public health system as well. In advancing our understanding of medical 
decision-making in advanced dementia and promoting less aggressive treatments, these 
studies are of direct relevance to the WHO global action plan on the public health response to 
dementia (World Health Organization, 2017). 
Study 1 informs research on the development of mortality risk scores for advanced 
dementia by demonstrating that the accuracy of proxy’s prognoses were modest, but 
remarkably similar to estimates that were based on the empirically derived Advanced 
Dementia Prognostic Tool (ADEPT; Mitchell, Miller, Teno, Kiely, Davis, & Shaffer, 2010b). 
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The ADEPT estimates prognosis based on factors such as the patient’s demographic, health, 
history and personality. Regardless of prognostic accuracy, however, the proxy perception 
that the resident may die within 6 months was associated with the use of fewer burdensome 
interventions. In advanced dementia, highly accurate prognostication may be elusive. 
However, a general understanding of the terminal nature of this condition may be pertinent to 
promoting a comfort-focused approach to care (Mitchell, Kiely, & Hamel, 2004a; van der 
Steen et al., 2013). As suggested by the findings in study 1, goals of care discussions with 
providers may be important for proxies to gain this understanding. The insight that it may not 
be the actual life expectancy of the patient but rather the prognosis perceptions of proxies that 
drive end-of-life care decisions is of tremendous value for clinical practice. During 
counseling, physicians could first establish the proxies’ perception of the life expectancy of 
the patient as a basis for how they subsequently provide prognostic information. This 
communication strategy could prevent misunderstanding between physicians and proxies (D. 
B. White et al., 2016a). Lastly, the fact that prognosis estimates of both mortality risk tools 
and key decision-makers are of limited accuracy is highly relevant for the U.S health care 
system. For example, patients can only access U.S. Medicare Hospice benefits and thus high-
quality palliative care, if they have an estimated life expectancy of 6 months or less (The 
National Hospice Organization, 1996). Providing access to this service based on the goals of 
care instead of the estimated life expectancy of a patient may thus be more appropriate.  
Study 2 informs research on the development of decision-support tools in advanced 
dementia and suggests that, compared to more elaborate video decision support tools, simple 
Fact Boxes may be equally effective, less expensive, handy and thus easier to incorporate into 
real-life settings. Resources that are currently used to develop and implement more elaborate 
tools could thus be made available to support other kinds of improvements. Moreover, and 
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more importantly for the current purposes, study 2 informs research on the development of 
Fact Boxes for other medical topics (McDowell et al., 2016). Our Fact Boxes for advanced 
dementia were effective despite the fact that they displayed relatively little evidence 
compared to previous Fact Boxes that relied on a richer basis of evidence. Because Fact 
Boxes benefited various decision-makers, research should tailor decision supports to 
physicians, relatives, but also to professional guardians, as they constitute an understudied 
population. Given the public health threat of MDROs, the Fact Box on the use of antibiotics 
in advanced dementia could be a promising tool for reducing the global burden of the spread 
of MDROs (Ho et al., 2010; World Health Organization, 2014b). If Fact Boxes are found to 
be also effective in real-life settings, they would be exactly the kind of material that could be 
shared on the WHO’s newly developed global dementia observatory platform (World Health 
Organization, 2016). 
Study 3 informs research on assisted dying and continuous deep sedation in advanced 
dementia and provides preliminary but novel findings about physicians’ and proxies’ 
opinions about the use of these practices. In general, there is a clear need to improve end-of-
life care in patients with advanced dementia, but it remains controversial whether such 
practices could contribute to this goal. While assisted dying is illegal in most countries,(E. J. 
Emanuel et al., 2016; Li et al., 2017) findings about the relative reluctance of physicians 
compared to proxies may be interesting for countries that consider extending legalization to 
patients with advanced dementia. For the Netherlands, Belgium, and Luxembourg, where 
assisted dying is legal, these findings may suggest that physicians and proxies could benefit 
from increased ethical guidance and support, respectively (Neil, 2016). Regarding both 
assisted dying and continuous deep sedation, perceptions were divided and less than half of 
the decision-makers would support these practices. In the face of likely disagreement 
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between decision-makers in real-world practice contexts, a shared-decision-making process 
that is mediated by standardized decision supports might play a substantial role in 
coordinating medical decision-making. 
This thesis has tackled several topics of high priority: dementia, palliative care, 
medical decision-making, prognosis, risk communication, MDROs, assisted dying, and 
continuous deep sedation. The management of patients with advanced dementia is a global 
burden and concern, and the three studies presented here contribute to promoting well-being 
in both decision-makers and patients affected by dementia. Lastly, this thesis may provide a 
basis for discussion and reinterpretation of the concept of Healthy Ageing in individuals with 
chronic and terminal illness who are no longer able to make decisions. 
6.7. Going Forward 
This thesis has provided support for the notion that goals of care discussions and brief 
decision support tools tailored to various decision-makers are key resources for medical 
decision-making. Therefore, future contributions should investigate how and when to best use 
these resources. 
The data presented in study 1 did not capture the content of goals of care discussions, 
rendering the specific factors that impacted proxies’ perception about a poor prognosis 
unclear. Because perception of prognosis may drive end-of-life decisions, structured 
communication support tools that share the advantages of Fact Boxes but focus on proxies’ 
perceptions could be promising. Given the implications outlined above, developing effective, 
standardized material to guide goals of care discussions to be used in practice is a research 
priority. 
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The clinical course of patients with advanced dementia has not been well described in 
Switzerland, and more data is needed to better understand the needs at the end of life that 
might be specific to this population. Fact Box decision support tools have been found to be 
effective in hypothetical situations, and a clinical trial could examine their impact in real-life 
settings. As discussed in the previous chapter, however, Fact Boxes are not mean to be used 
in isolation. Rather, decision-support tools should be an integral part of a larger intervention 
that helps communicate treatment effects in advanced dementia (see for example Hanson et 
al. 2017). Target populations necessarily include physicians but also nurses, relatives, and 
professional guardians. Outcomes should be analyzed separately for each population to 
capture and optimally address corresponding differences. Because decisions in the context of 
critical and terminal illness affect decision-makers beyond the confined space of observed 
medical settings, it could prove insightful to assess the effects of Fact Boxes on decision-
makers’ daily lives and reflections beyond those settings. Future work should examine 
whether the Fact Box on the use of antibiotics in advanced dementia is a suitable measure to 
reduce the public health burden of MDROs in Switzerland and other countries.  
Of direct relevance to end-of-life decision-making in advanced dementia, study 3 has 
explored the perceptions of physicians and proxies about assisted dying and continuous deep 
sedation. Because these findings were based on secondary analyses of the DEMFACT study, 
a replication study with these variables as primary outcomes could serve to confirm our 
preliminary findings. As in study 3, such a replication should employ a mixed methods 
design to elucidate which factors have influenced participants’ perceptions about the use of 
these practices. Furthermore, it would also be of interest to examine how increased guidance 
and support affect subsequent perceptions.  
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6.8. Conclusion 
From a healthy ageing perspective, patients with advanced dementia who lack 
decision-making capacities need to rely on the ability of decision-makers to anticipate, 
recognize and fulfill their end-of-life needs in order to enable well-being despite or with 
dementia and until death. In this sense, decision-makers may represent the most important 
resource for patients with advanced dementia in order to ensure that they can be and to do 
what they have reason to value (p. 28) despite their inability to make decisions (World Health 
Organization, 2015b). Crucially, however, the corresponding decisions affect not only the 
well-being of the patient but also that of the decision-maker. Therefore, high-quality medical 
decision-making in advanced dementia may be characterized by the degree to which it 
enables well-being and in turn healthy ageing in both decision-makers and patients. 
In this thesis, goals of care discussions and brief Fact Box decision support tools 
improved medical decision-making in advanced dementia in various decision-makers, and 
resulted in better outcomes for patients as well. Put briefly, goals of care discussions and Fact 
Boxes are resources for high-quality decision-making, which positively influence end-of-life 
care. A future clinical trial could further assess decision-making of residents with advanced 
dementia in Switzerland by testing the efficacy of Fact Box decision support tools in direct 
communication during goals of care discussions. With respect to controversial end-of-life 
practices, decision-makers showed no consensus on whether assisted dying and continuous 
deep sedation should be seen as valid options in advanced dementia. Future work may 
elucidate the reasons that underlie these perceptions. 
This thesis has examined the concept of Healthy Ageing in light of the delicate 
challenges of end-of-life decision-making: the degree to which decisions can be made in 
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accordance with the patients’ preferences depends in no small part on the perceptions, 
knowledge, and values of the decision maker. In establishing this intricate interrelation, this 
thesis touched on many global public health priority topics such as dementia and palliative 
care and highlighted far-reaching implications for the improvement of medical decision-
making and care management in advanced dementia in Switzerland and beyond. 
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8. Appendix A 
Main Results of Study 1 Presented for Both Study Cohorts Combined, and Each Study 
Separately 
Appendix 1. Association between the Proxy Prognostic Estimates and Risk of Death among 
Nursing Home Residents with Advanced Dementia Dying in SPREAD 
(N=362), EVINCE (N=402), and Two Studies Combined (N=764) 
Appendix 2. Adjusted Association between the Proxy Being Asked About Goals of Care and 
the Proxy’s Perception that the Resident with Advanced Dementia had Less 
Than 6 Months to Live in SPREAD (N=362), EVINCE (N=402), and Two 
Studies Combined (N=764) 
Appendix 3. Adjusted Association between the Proxy’s Perception that the Resident had Less 
than 6 Months to Live and Use of Any Burdensome Interventions among 
Nursing Home Residents with Advanced Dementia in SPREAD (N=362), 
EVINCE (N=402), and Two Studies Combined (N=764) 
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Appendix A1. Association between the Proxy Prognostic Estimates and Risk of Death among Nursing Home 
Residents with Advanced Dementia Dying in SPREADa (N=362), EVINCEa (N=402), and Two Studies 
Combined (N=764)b 
Study 
Cohort 
Adjusted Hazard Ratioc (95% Confidence Interval) 
Accuracy of 
Proxy 
Prognosisd 
< 1 Month 1-6 Months 7-12 Months 
Don’t 
Know/Refused c Statistic 
Combined  27.53 (15.81, 47.95) 4.61 (3.12, 6.79) 1.91 (1.38, 2.64) 0.92 (0.40, 2.14) 0.67 
SPREAD 33.49 (10.26, 109.31) 4.47 (3.13, 6.38) 2.34 (1.55, 3.54) 1.53 (0.62, 3.79) 0.65 
EVINCE 24.04 (12.66, 45.63) 4.47 (2.58, 7.73) 1.62 (1.02, 2.57) 0.28 (0.04, 1.99) 0.68 
aSPREAD = the Study of Pathogen Resistance and Exposure to Antimicrobials in Dementia; EVINCE = the Educational Video to Improve 
Nursing home Care in End-stage dementia. 
bThe distribution of the proxy prognostic estimates at all proxy interviews (N=2649 interviews) for the combined cohort was: < 1 month, 
N=30 (1.1%); 1-6 months, N=279 (10.5%); 7-12 months, N=664 (25.1%); > 12 months, N=1553 (58.6%); and don’t know/refused, 
N=123 (4.6%). In SPREAD (N=1236 interviews); < 1 month, N=11 (0.9%); 1-6 months, N=99 (8.0%); 7-12 months, N=269 (21.8%); > 
12 months, N=790 (63.9%); and don’t know/refused, N=67 (5.4%). In EVINCE (N =1413 interviews); <1 month, N=19 (1.3%); 1-6 
months, N=180 (12.7%); 7-12 months, N=395 (28.0%); > 12 months, N=763 (54.0%); and don’t know/refused, N=56 (4.0%).  
cCox proportional hazards regression examined associations between prognostic estimates at each interview date and the risk of the 
resident dying given that the resident had survived up until that point. Survival times between 6 and 7 months were rounded up or down. 
Robust standard errors accounted for clustering at the facility-level. 
dGeneralized version of the c statistic allowing for censored data was calculated as a measure of the model’s overall accuracy (range 0.5-
1, higher scores indicate greater accuracy). 
 
Appendix A2. Adjusted Association between the Proxy Being Asked About Goals of Care and the Proxy’s 
Perception that the Resident with Advanced Dementia had Less Than 6 Months to Live in SPREADa (N=362), 
EVINCEa (N=402), and Two Studies Combined (N=764)b 
  Total No. (%) of 
Assessment Intervals at 
Which Proxies Reported 
Being Asked About Goals 
of Carec 
No. (%) of Assessment Intervals at Which Proxy 
Estimated Resident had < 6 Months to Live Adjusted Odds 
Ratiod (95% 
Confidence 
Interval) 
Study 
Cohort 
When Proxies were 
Asked About Goals of 
Care 
When Proxies were not 
Asked About Goals of 
Care 
Combined 1126/2526 (44.6) 183 (7.2) 126 (5.0) 1.94 (1.50, 2.52) 
SPREAD 525/1169 (44.9) 70 (6.0) 40 (3.4) 2.17 (1.36, 3.46) 
EVINCE 601/1357 (44.3) 113 (8.3) 86 (6.3) 1.78 (1.30, 2.44) 
aSPREAD = the Study of Pathogen Resistance and Exposure to Antimicrobials in Dementia; EVINCE = the Educational Video to Improve 
Nursing home Care in End-stage dementia. 
bProportion of the proxy interviews with prognostic estimates < 6 months; combined cohort, N=309/2526 (12%); SPREAD, N=110/1169 
(9.4%); and EVINCE, N=199/1357 (14.7%). 
cAnalyses were at the level of assessment intervals. Resident chart reviews and proxy interviews were done at baseline and quarterly for up 
to 12 months. Static variables were brought forward from baseline. Proxy’s perception of prognosis and other dynamic variables (e.g., 
goals of care discussion, hospital transfers) were ascertained from each assessment period. 
dAdjusted odds ratio accounted for clustering among resident/proxy dyads using generalized estimating equations. The model was adjusted 
for the following variables: resident age (dichotomized at median), resident gender, resident race (white versus other), Alzheimer’s versus 
other dementia type, chronic obstructive pulmonary disease, congestive heart failure, diabetes, Test for Severe Impairment = 0 (versus > 
0) (range 0-24, lower scores indicate greater cognitive impairment), Bedford Alzheimer’s Nursing Severity-Subscale score > 21 (range 7-
28, higher scores indicate more disability), hospital transfer in prior 3 months, proxy age (dichotomized at median), proxy gender, and 
proxy relationship to resident.  
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Appendix A3. Adjusted Association between the Proxy’s Perception that the Resident had Less than 6 Months 
to Live and Use of Any Burdensome Interventionsa among Nursing Home Residents with Advanced Dementia 
in SPREADb (N=362), EVINCEb (N=402), and Two Studies Combined (N=764)c 
  Total No. (%) of 
Assessment Intervals in 
Which Proxy Estimated 
Resident Prognosis < 6 
Monthsd 
No. (%) of Assessment Intervals in Which 
Resident had Any Burdensome 
Interventions 
Adjusted Odds 
Ratioe (95% 
Confidence Interval) Study Cohort 
When Proxy 
Estimated Prognosis 
< 6 Months 
When Proxy 
Estimated Prognosis 
> 6 Months 
Combined 251/2031 (12.4) 89 (4.4) 1008 (49.6) 0.46 (0.34, 0.62) 
SPREAD 87/928 (9.4) 38 (4.1) 480 (51.7) 0.60 (0.35, 1.02) 
EVINCE 164/1103 (14.9) 51 (4.6) 528 (47.9) 0.40 (0.27, 0.57) 
aBurdensome interventions included any of the following: hospital transfer (hospitalization or emergency room visits), parenteral therapy, 
new feeding tube insertion, venipuncture and bladder catheterizations. 
bSPREAD = the Study of Pathogen Resistance and Exposure to Antimicrobials in Dementia; EVINCE = the Educational Video to Improve 
Nursing home Care in End-stage dementia. 
cIn the combined cohort at all resident-assessment intervals (i.e., baseline and follow-up; N=2031) the proportion of intervals during 
which residents experienced at least one burdensome intervention was: combined cohort, N=1097/2037 (54.0%); SPREAD, N=518/928 
(55.8%); and EVINCE, N=579/1103 (52.5%). 
dAnalyses were at the level of assessment intervals. Resident chart reviews and proxy interviews were done at baseline and quarterly for up 
to 12 months. Proxy prognosis was taken from the interview done at the start of the interval. The use of burdensome interventions reflects 
the residents experience during the 3-month interval following that interview.  
e Adjusted odds ratio accounted for clustering among resident/proxy dyads using generalized estimating equations. The model was 
adjusted for the following variables: resident age (dichotomized at median), resident gender, resident race (white versus other), 
Alzheimer’s versus other dementia type, chronic obstructive pulmonary disease, congestive heart failure, diabetes, Test for Severe 
Impairment = 0 (versus > 0) (range 0-24, lower scores indicate greater cognitive impairment), Bedford Alzheimer’s Nursing Severity-
Subscale score > 21 (range 7-28, higher scores indicate more disability), any new major illness in prior 3 months, proxy age 
(dichotomized at median), proxy gender, proxy relationship to resident, and goals of care discussions. 
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9. Appendix B 
Supplementary Material of Study 2 
Appendix 1. Fact Box Decision Support Tool: Antibiotics For Pneumonia in Advanced 
Dementia 
Appendix 2. Fact Box Decision Support Tool: Artificial Hydration in Advanced Dementia 
Appendix 3. Knowledge Scale About the Use of Antibiotics for Pneumonia in Advanced 
Dementia  
Appendix 4. Knowledge Scale About the Use of Artificial Hydration in Advanced Dementia 
Appendix 5. The CONSORT flow diagram of participant subgroups 
Appendix 6. Distribution of Missing Values in Decisional Conflict Scores by Trial Arm, and 
for Each Participant Subgroup Separately 
Appendix 7. Distribution of Missing Values in Knowledge Scores and Preferences to Forego 
Antibiotics and Artificial Hydration by Trial Arm, and for Each Participant 
Subgroup Separately  
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Appendix B1. Fact Box Decision Support Tool: Antibiotics For Pneumonia in Advanced 
Dementia 
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Appendix B2. Fact Box Decision Support Tool: Artificial Hydration in Advanced Dementia 
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Appendix B3. Knowledge Scale About the Use of Antibiotics for Pneumonia in Advanced 
Dementia 
The DemFACT trial ascertained participant’s knowledge about the use of antibiotics 
for pneumonia in advanced dementia using a 7-item true-false scale in German (scored, 
1=true, 0=false/don’t know; range 0-7, higher scores indicate greater knowledge). For the 
purpose of this report the scale has been translated into English (see next page).  
 
Original German Version: 
 
In diesem Teil möchten wir gerne wissen, was Sie über Antibiotika gegen Lungenentzündung 
bei fortgeschrittener Demenz wissen. Versuchen Sie die Fragen so gut wie möglich zu 
beantworten. 
Was wissen Sie über den Einsatz von Antibiotika bei Patienten/innen mit fortgeschrittener 
Demenz und Lungenentzündung?  
  
Richtig Falsch 
Weiss 
nicht 
A Nutzen von Antibiotika gegen Lungenentzündung bei 
fortgeschrittener Demenz    
a Antibiotika können das Leben um ein paar Tage, jedoch 
nicht um mehr als einen Monat, verlängern. 
 
£ £ £ 
b Die Gabe von Antibiotika erleichtert Atembeschwerden 
stärker, als wenn keine Antibiotika verabreicht werden. 
 
£ £ £ 
c Die Gabe von Antibiotika lindert Schmerzen stärker, als 
wenn keine Antibiotika verabreicht werden. £ £ £ 
d Antibiotika bei einer Lungenentzündung können das Leben 
um mehr als einen Monat verlängern. £ £ £ 
B Risiken von Antibiotika gegen Lungenentzündung bei 
fortgeschrittener Demenz    
a Antibiotika haben keine bedeutsamen Nebenwirkungen. 
 £ £ £ 
b Durchfall, allergische Reaktionen (z.B. Hautausschläge), 
Übelkeit oder Erbrechen sind Nebenwirkungen von 
Antibiotika. 
£ £ £ 
c Blutdruckanstieg, Gewichtszunahme oder Osteoporose sind 
Nebenwirkungen von Antibiotika. £ £ £ 
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English translation: 
In this section, we are interested in your knowledge about the use of antibiotics for 
pneumonia in advanced dementia. Try to answer the questions as best you can.  
What do you know about the administration of antibiotics for patients with advanced dementia 
and pneumonia? 
 N=Correct / N=Total (%)a 
 Intervention, N=114 Control, N=118 
A Benefits of Antibiotics for Pneumonia in 
Advanced Dementia    
a Antibiotics can prolong life by a couple of days, but 
not by more than one month. 70/112 (62.5) 15/118 (12.7) 
b The administration of antibiotics relieves breathing 
difficulties more than if no antibiotics are 
administered.  
84/112 (75.0) 34/117 (29.1) 
c The administration of antibiotics alleviates pain 
more than if no antibiotics are administered.  89/112 (79.5) 43/118 (36.4) 
d Antibiotics for pneumonia can prolong life by more 
than one month. 86/112 (76.8) 19/118 (16.1) 
B Harms of Antibiotics for Pneumonia in 
Advanced Dementia    
a Antibiotics cannot cause significant adverse events.  98/111 (88.3) 97/117 (82.9) 
b Diarrhea, allergic reactions (e.g., skin rashes), 
nausea or vomiting are adverse events of 
antibiotics. 
88/111 (79.3) 93/118 (78.8) 
c Hypertension, weight gain, or osteoporosis are 
adverse events of antibiotics.  80/112 (71.4) 50/118 (42.4) 
aNumber of correct responses (versus number of wrong or don’t know responses) by total number of 
observations per item were taken from the one-month follow-up assessment for the intervention and control 
arms. 
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Appendix B4. Knowledge Scale About the Use of Artificial Hydration in Advanced 
Dementia 
The DemFACT trial ascertained participant’s knowledge about the use of artificial 
hydration in advanced dementia using a 7-item true-false scale in German (scored, 1=true, 
0=false/don’t know; range 0-7, higher scores indicate greater knowledge). For the purpose of 
this report the scale has been translated into English (see next page). 
Original German Version: 
In diesem Teil möchten wir gerne wissen, was Sie über künstliche Flüssigkeitszufuhr bei 
fortgeschrittener Demenz wissen. Versuchen Sie die Fragen so gut wie möglich zu 
beantworten.  
Was wissen Sie über den Einsatz von künstlicher Flüssigkeitszufuhr bei Patienten/innen mit 
fortgeschrittener Demenz und Flüssigkeitsmangel (Dehydration)?  
  
Richtig Falsch 
Weiss 
nicht 
A Nutzen von künstlicher Flüssigkeitszufuhr bei 
fortgeschrittener Demenz (oder Krebserkrankung)    
a Es gibt nicht genügend Daten über die Wirkung von 
Künstlicher Flüssigkeitszufuhr auf die Sterblichkeit von 
Patienten/innen mit einer fortgeschrittenen Demenz. 
£ £ £ 
b Es gibt nicht genügend Daten über die Wirkungen von 
künstlicher Flüssigkeitszufuhr auf die Schmerzen der 
Patienten/innen mit fortgeschrittener Demenz. 
£ £ £ 
c Künstliche Flüssigkeitszufuhr kann bei Patienten/innen mit 
einer fortgeschrittenen Krebserkrankung das Leben um 
einige Tage, jedoch nicht um mehr als einen Monat, 
verlängern. 
£ £ £ 
d Künstliche Flüssigkeitszufuhr lindert bei Patienten/innen 
mit einer fortgeschrittenen Krebserkrankung die Schmerzen 
stärker, als wenn keine künstliche Flüssigkeitszufuhr 
veranlasst wird. 
£ £ £ 
B Risiken von künstlicher Flüssigkeitszufuhr bei 
fortgeschrittener Demenz    
a Künstliche Flüssigkeitszufuhr hat keine bedeutsamen 
Nebenwirkungen. £ £ £ 
b Unnatürliche Ansammlung von Flüssigkeit im Bereich der 
Lunge (Lungenödem) oder in den Beinen sind 
Nebenwirkungen von künstlicher Flüssigkeitszufuhr. 
£ £ £ 
c Entzündungen am venösen Zugang (Einstichort) sind 
Nebenwirkungen von künstlicher Flüssigkeitszufuhr. £ £ £ 
  
APPENDIX 
 
119 
English translation: 
In this section, we are interested in your knowledge about the use of artificial hydration in 
advanced dementia. Try to answer the questions as best you can.  
What do you know about the administration of artificial hydration for patients with advanced 
dementia and suspected insufficient fluid intake (dehydration)? 
 N=Correct / N=Total (%)a 
 Intervention, 
N=114 
Control, 
N=118 
A Benefits of Artificial Hydration in Advanced 
Dementia (or Advanced Cancer)   
a There are insufficient data about the effects of 
artificial hydration on survival of patients with 
advanced dementia. 
106/113 (93.8) 26/117 (22.2) 
b There are insufficient data about the effects of 
artificial hydration on the pain experienced by 
patients with advanced dementia. 
105/114 (92.1) 29/118 (24.6) 
c Artificial hydration can prolong the life of patients 
with advanced cancer by a couple of days, but not 
by more than one month.  
50/113 (44.2) 20/118 (16.9) 
d Artificial hydration alleviates the pain experienced 
by patients with advanced cancer more than if no 
artificial hydration is administered. 
91/111 (82.0) 53/118 (44.9) 
B Harms of Artificial Hydration in Advanced 
Dementia   
a Artificial hydration cannot cause significant 
adverse events. 96/113 (85.0) 65/117 (55.6) 
b Abnormal accumulation of fluid in the lungs 
(pulmonary oedema) or legs are adverse events of 
artificial hydration. 
106/114 (93.0) 60/118 (50.9) 
c Local infections at the injection site (the venous 
access where the needle is placed) are adverse 
events of artificial hydration. 
105/114 (92.1) 78/118 (66.1) 
aNumber of correct responses (versus number of wrong or don’t know responses) by total number of 
observations per item were taken from the one-month follow-up assessment for the intervention and control 
arms. 
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Appendix B5. CONSORT flow diagram of participant subgroups. The total number of 
eligible physicians, relatives of dementia patients, and professional guardians who were 
approached are approximations provided by the organizations that helped with recruitment. 
 
  
3606 Did not respond 
   486 Physicians  
   1797 Relatives  
   1323 Professional guardians 
3860 Eligible participants approached 
   560 Physicians  
   1900 Relatives 
   1400 Professional guardians 
254 Contacted our group for participation 
and were randomized 
   74 Physicians 
   103 Relatives  
   77 Professional guardians 
 4 Physicians unable to contact 
 1 Relative withdrew 
 5 Professional guardians 
    3 withdrew, 2 unable to contact 
 1 Physician unable to contact 
 1 Relative withdrew 
 1 Professional guardian unable to 
    contact 
 3 Physicians unable to contact 
 1 Professional guardian unable to 
    contact 
 2 Physicians 
    1 withdrew, 1 unable to contact 
 1 Relative withdrew 
 2 Professional guardians unable to 
    contact 
128 Intervention 
   37 Physicians 
   52 Relatives 
   39 Professional guardians 
126 No intervention 
   37 Physicians 
   51 Relatives 
   38 Professional guardians 
123 Completed baseline 
   36 Physicians 
   50 Relatives 
   37 Professional guardians 
118 Completed baseline 
   33 Physicians 
   51 Relatives 
   34 Professional guardians 
118 Completed one-month follow-up 
   34 Physicians 
   49 Relatives 
   35 Professional guardians 
114 Completed one-month follow-up 
   30 Physicians 
   51 Relatives 
   33 Professional guardians 
114 Included in analyses 
   30 Physicians 
   51 Relatives 
   33 Professional guardians 
118 Included in analyses 
   34 Physicians 
   49 Relatives 
   35 Professional guardians 
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Appendix B6. Distribution of Missing Values in Decisional Conflict Scores by Trial Arm, and for Each 
Participant Subgroup Separately 
Participants 
Baseline 
No. Missing/No. Total, (%) 
1 Month 
No. Missing/No. Total, (%) 
Intervention Control 
Intervention, 
Review 
Fact Box Control 
All, N=232     
Decisional conflict about     
Antibiotic use 8/114 (7.0) 5/118 (4.2) 6/114 (5.3) 4/118 (3.4) 
Artificial hydration use 10/114 (8.8) 7/118 (5.9) 8/114 (7.0) 6/118 (5.1) 
Physicians, N=64     
Decisional conflict about     
Antibiotic use - - 1/30 (3.3) 1/34 (2.9) 
Artificial hydration use 1/30 (3.3) - 3/30 (10.0) - 
Relatives, N=100     
Decisional conflict about     
Antibiotic use 6/51 (11.8) 3/49 (6.1) 3/51 (5.9) 1/49 (2.0) 
Artificial hydration use 8/51 (15.7) 5/49 (10.2) 3/51 (5.9) 4/49 (8.2) 
Professional Guardians, N=68     
Decisional conflict about     
Antibiotic use 2/33 (6.1) 2/35 (5.7) 2/33 (6.1) 2/35 (5.7) 
Artificial hydration use 1/33 (3.0) 2/35 (5.7) 2/33 (6.1) 2/35 (5.7) 
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Appendix B7. Distribution of Missing Values in Knowledge Scores and Preferences to Forego Antibiotics and 
Artificial Hydration by Trial Arm, and for Each Participant Subgroup Separately 
Participants 
Baseline 
No. Missing/No. Total, (%) 
1 Month 
No. Missing/No. Total, (%) 
Intervention Control 
Interventio, 
Review 
Fact Box Control 
All, N=232     
Knowledge about     
Antibiotics use 4/114 (3.5) 6/118 (5.1) 3/114 (2.6) 2/118 (1.7) 
Artificial hydration use 3/114 (2.6) 3/118 (2.5) 4/114 (3.5) 2/118 (1.7) 
Preferences to forego     
Antibiotic use 1/114 (0.9) 2/118 (1.7) 1/114 (0.9) - 
Artificial hydration use - 1/118 (0.8) 1/114 (0.9) - 
Physicians, N=64     
Knowledge about     
Antibiotic use - 2/34 (5.9) - 1/34 (2.9) 
Artificial hydration use 1/30 (3.3) - 1/30 (3.3) 1/34 (2.9) 
Preferences to forego     
Antibiotic use - - - - 
Artificial hydration use - - - - 
Relatives, N=100     
Knowledge about     
Antibiotic use 4/51 (7.8) 2/49 (4.1) 3/51 (5.9) - 
Artificial hydration use 1/51 (2.0) 2/49 (4.1) 2/51 (3.9) 1/49 (2.0) 
Preferences to forego     
Antibiotic use - 1/49 (2.0) 1/51 (2.0) - 
Artificial hydration use - - 1/51 (2.0) - 
Professional Guardians, N=68     
Knowledge about     
Antibiotic use - 2/35 (5.7) - 1/35 (2.9) 
Artificial hydration use 1/33 (3.0) 1/35 (2.9) 1/33 (3.0) - 
Preferences to forego     
Antibiotic use 1/33 (3.0) 1/35 (2.9) - - 
Artificial hydration use - 1/35 (2.9) - - 
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